US20090306739A1 - Methods and apparatus for neuromodulation and physiologic modulation for the treatment of obesity and metabolic and neuropsychiatric disease - Google Patents
Methods and apparatus for neuromodulation and physiologic modulation for the treatment of obesity and metabolic and neuropsychiatric disease Download PDFInfo
- Publication number
- US20090306739A1 US20090306739A1 US12/462,903 US46290309A US2009306739A1 US 20090306739 A1 US20090306739 A1 US 20090306739A1 US 46290309 A US46290309 A US 46290309A US 2009306739 A1 US2009306739 A1 US 2009306739A1
- Authority
- US
- United States
- Prior art keywords
- modulator
- stimulation
- spinal
- sympathetic
- neuromodulatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36007—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation of urogenital or gastrointestinal organs, e.g. for incontinence control
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/0551—Spinal or peripheral nerve electrodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
- A61N1/36114—Cardiac control, e.g. by vagal stimulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N2/00—Magnetotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
Definitions
- the present invention relates generally to metabolic disease and neuropsychiatric disease and, more particularly, to stimulation of gastric and sympathetic neural tissue for the treatment of obesity and depression.
- VMH left ventromedial hypothalamic
- Gastric distension modulates hypothalamic neurons via a sympathetic afferent path through the mesencephalic periaqueductal gray. Brain Research Bulletin. 38: 239-51.] This modulation of the hypothalamus was attenuated but not permanently eliminated by bilateral transection of the vagus nerve. This modulation was, however, significantly reduced or eliminated by bilateral transection of the cervical sympathetic chain or spinal transection at the first cervical level. [Barone, Zarco de Coronado et al. (1995). Gastric distension modulates hypothalamic neurons via a sympathetic afferent path through the mesencephalic periaqueductal gray. Brain Research Bulletin.
- VNS Nonselective epineural vagus nerve stimulation
- the vagus nerve is well known to mediate gastric hydrochloric acid secretion. Dissection of the vagus nerve off the stomach is often performed as part of major gastric surgery for ulcers. Stimulation of the vagus nerve may pose risks for ulcers in patients, of particular concern, as obese patients often have gastroesophageal reflux disease (GERD); further augmentation of gastric acid secretion would only exacerbate this condition.
- GFD gastroesophageal reflux disease
- the present invention teaches a significantly more advanced neuroelectric interface technology to stimulate the vagus nerve and avoid the efferent vagus side effects, including speech and cardiac side effects common in with existing VNS technology as well as the potential ulcerogenic side effects.
- efferent vagus side effects including speech and cardiac side effects common in with existing VNS technology as well as the potential ulcerogenic side effects.
- sympathetic afferent activity appears more responsive to gastric distension, this may represent a stronger channel for modulating satiety.
- pacing stimulating modulators on the greater curvature of the stomach, one may stimulate the majority of the circular layer of gastric musculature, thereby diffusely increasing gastric tone.
- the muscular layer of the stomach is comprised of 3 layers: (1) an outer longitudinal layer, (2) a circular layer in between, and (3) a deeper oblique layer.
- the circular fibers which lie deep to the superficial longitudinal fibers, would appear to be the layer of choice for creating uniform and consistent gastric contraction with elevated wall tension and luminal pressure. Therefore, modulators should have the ability to deliver stimulation through the longitudinal layer. If the modulator is in the form of an electrode, then the electrodes should have the ability to deliver current through the longitudinal layer.
- Gray's Anatomy describes innervation as including the right and left pneumogastric nerves (not the vagus nerves), being distributed on the back and front of the stomach, respectively. A great number of branches from the sympathetic nervous system also supply the stomach. [Gray (1974). Gray's Anatomy. T. Pick and R. Howden. Philadelphia, Running Press.]
- the VMH is a hypothalamic component of the sympathetic nervous system. [Ban (1975). Fiber connections in the hypothalamus and some autonomic functions. Pharmacology Biochemistry & Behavior. 3: 3-13.]
- thermogenic response in BAT was observed with direct sympathetic nerve stimulation.
- the BAT had abundant sympathetic innervation with adrenergic fibers that form nest-like networks around every fat cell, [Derry, Schonabum et al. (1969). Two sympathetic nerve supplies to brown adipose tissue of the rat. Canad. J. Physiol. Pharmacol. 47: 57-63.] whereas WAT has no adrenergic fibers in direct contact with fat cells except those related to the blood vessels. [Daniel and Derry (1969). Criteria for differentiation of brown and white fat in the rat. Canad. J. Physiol. Pharmacol. 47: 941-945.]
- the present invention teaches apparatus and methods for treating a multiplicity of diseases, including obesity, depression, epilepsy, diabetes, and other diseases.
- the invention taught herein employs a variety of energy modalities to modulate central nervous system structures, peripheral nervous system structures, and peripheral tissues and to modulate physiology of neural structures and other organs, including gastrointestinal, adipose, pancreatic, and other tissues.
- the methods for performing this modulation, including the sites of stimulation and the modulator configurations are described.
- the apparatus for performing the stimulation are also described.
- This invention teaches a combination of novel anatomic approaches and apparatus designs for direct and indirect modulation of the autonomic nervous system, which is comprised of the sympathetic nervous system and the parasympathetic nervous system.
- GastroPace should be interpreted to mean the devices constituting the system of the present embodiment of this invention.
- the present invention teaches several mechanisms, including neural modulation and direct contraction of the gastric musculature, to effect the perception of satiety. This modulation is useful in the treatment of obesity and eating disorders, including anorexia nervosa and bulimia.
- Direct stimulation of the gastric musculature increases the intraluminal pressure within the stomach; and this simulates the physiologic condition of having a full stomach, sensed by stretch receptors in the muscle tissue and transmitted via neural afferent pathways to the hypothalamus and other central nervous system structures, where the neural activity is perceived as satiety.
- Stimulation of any of the gastric fundus, greater curvature of stomach, pyloric antrum, or lesser curvature of stomach, or other region of the stomach or gastrointestinal tract increases the intraluminal pressure. Increase of intraluminal pressure physiologically resembles fullness of the respective organ, and satiety is perceived.
- the present invention also includes the restriction of the flow of food to effect satiety. This is accomplished by stimulation of the pylorus.
- the pylorus is the sphincter-like muscle at the distal juncture of the stomach with the duodenum, and it regulates food outflow from the stomach into the duodenum.
- By stimulating contraction of the pylorus food outflow from the stomach is slowed or delayed.
- the presence of a volume of food in the stomach distends the gastric musculature and causes the person to experience satiety.
- the present invention includes electrical stimulation of peripheral nervous system and other structures and tissues to modulate the activity in the central nervous system to control seizure activity.
- This modulation takes the form of peripheral nervous system stimulation using a multiplicity of novel techniques and apparatus.
- Direct stimulation of peripheral nerves is taught; this includes stimulation of the vagus, trigeminal, accessory, and sympathetic nerves.
- Indiscriminate stimulation of the vagus nerves has been described for some disorders, but the limitations in this technique are substantial, including cardiac rhythm disruptions, speech difficulties, and gastric and duodenal ulcers.
- the present invention overcomes these persistent limitations by teaching a method and apparatus for the selective stimulation of structures, including the vagus nerve as well as other peripheral nerves, and other neural, neuromuscular, and other tissues.
- the present invention further includes noninvasive techniques for neural modulation.
- This noninvasive stimulation includes the use of tactile stimulation, including light touch, pressure, vibration, and other modalities that may be used to activate the peripheral or cranial nerves.
- Temperature stimulation including hot and cold, as well as constant or variable temperatures, are included in the present invention.
- the response of the gastrointestinal system, including the pancreas, to a meal includes several phases.
- the first phase, the anticipatory stage, is neurally mediated.
- saliva production increases and the gastrointestinal system prepares for the digestion of the food to be ingested.
- Innervation of the pancreas in an analogous manner, controls production of insulin.
- Modulation of pancreatic production of insulin may be performed by modulation of at least one of afferent or efferent neural structures.
- Afferent modulation of at least one of the vagus nerve, the sympathetic structures innervating the gastrointestinal tissue, the sympathetic trunk, and the gastrointestinal tissues themselves is used as an input signal to influence central and peripheral nervous system control of insulin secretion.
- FIG. 1 depicts GastroPace implanted along the Superior Greater Curvature of the stomach for both Neural Afferent and Neuromuscular Modulation
- FIG. 2 depicts GastroPace implanted along the Inferior Greater Curvature of the stomach for both Neural Afferent and Neuromuscular Modulation
- FIG. 3 depicts GastroPace implanted along the Pyloric Antrum of the stomach for both Neural Afferent and Neuromuscular Modulation
- FIG. 4 depicts GastroPace implanted adjacent to the Gastric Pylorus for modulation of pylorus activity and consequent control of gastric food efflux and intraluminal pressure
- FIG. 5 depicts GastroPace implanted along the Pyloric Antrum of the stomach with modulators positioned for stimulation of Neural and Neuromuscular structures of the Pylorus and Pyloric Antrum of the Stomach
- FIG. 6 depicts GastroPace implanted along the Pyloric Antrum of the stomach with modulators positioned for stimulation of Neural and Neuromuscular structures of the Pylorus, Pyloric Antrum, Greater Curvature, and Lesser Curvature of the Stomach
- FIG. 7 depicts the Nerve Cuff Electrode, comprising the Epineural Electrode Nerve Cuff Design
- FIG. 8 depicts the Nerve Cuff Electrode, comprising the Axial Electrode Blind End Port Design
- FIG. 9 depicts the Nerve Cuff Electrode, comprising the Axial Electrode Regeneration Port Design
- FIG. 10 depicts the Nerve Cuff Electrode, comprising the Axial Regeneration Tube Design
- FIG. 11 depicts GastroPace implanted along the Pyloric Antrum of the stomach with modulators positioned for stimulation of Afferent Neural Structures, including sympathetic and parasympathetic fibers
- FIG. 12 depicts GastroPace implanted along the Pyloric Antrum of the stomach with modulators positioned for stimulation of Neural and Neuromuscular structures of the Pylorus, Pyloric Antrum, Greater Curvature, and Lesser Curvature of the Stomach and with modulators positioned for stimulation of Afferent Neural Structures, including sympathetic and parasympathetic fibers
- FIG. 13 depicts the Normal Thoracoabdominal anatomy as seen via a sagittal view of an open dissection
- FIG. 14 depicts modulators for GastroPace positioned on the sympathetic trunk and on the greater and lesser splanchnic nerves, both supradiaphragmatically and infradiaphragmatically, for afferent and efferent neural modulation.
- FIG. 15 depicts GastroPace configured with multiple pulse generators, their connecting cables, and multiple modulators positioned on the sympathetic trunk and on the greater and lesser splanchnic nerves, both supradiaphragmatically and infradiaphragmatically, for afferent and efferent neural modulation.
- FIG. 16 depicts GastroPace configured with multiple pulse generators, their connecting cables, and multiple modulators positioned on the sympathetic trunk and on the greater and lesser splanchnic nerves, both supradiaphragmatically and infradiaphragmatically, for afferent and efferent neural modulation and with modulators positioned for stimulation of Neural and Neuromuscular structures of the Pylorus, Pyloric Antrum, Greater Curvature, and Lesser Curvature of the Stomach
- FIG. 17 depicts the Normal Spinal Cord Anatomy, shown in Transverse Section
- FIG. 18 depicts GastroPace implanted with multiple modulators positioned for modulation of Spinal Cord structures
- the present invention encompasses a multimodal technique, method, and apparatus for the treatment of several diseases, including but not limited to obesity, eating disorders, depression, epilepsy, and diabetes.
- These modalities may be used for diagnostic and therapeutic uses, and these modalities include but are not limited to stimulation of gastric tissue, stimulation of gastric musculature, stimulation of gastric neural tissue, stimulation of sympathetic nervous tissue, stimulation of parasympathetic nervous tissue, stimulation of peripheral nervous tissue, stimulation of central nervous tissue, stimulation of cranial nervous tissue, stimulation of skin receptors, including Pacinian corpuscles, nociceptors, golgi tendons, and other sensory tissues in the skin, subcutaneous tissue, muscles, and joints.
- Stimulation may be accomplished by electrical means, optical means, electromagnetic means, radiofrequency means, electrostatic means, magnetic means, vibrotactile means, pressure means, pharmacologic means, chemical means, electrolytic concentration means, thermal means, or other means for altering tissue activity.
- Selected stimulation of the sympathetic nervous system is an objective of the present invention.
- a variety of modulator designs and configurations are included in the present invention and other designs and configurations may be apparent to those skilled in the art and these are also included in the present invention.
- Said modulator may take the form of electrode or electrical source, optical source, electromagnetic source, radiofrequency source, electrostatic source, magnetic source, vibrotactile source, pressure source, pharmacologic source, chemical source, electrolyte source, thermal source, or other energy or stimulus source.
- One objective of the modulator design for selective sympathetic nervous system stimulation is the avoidance of stimulation of the vagus nerve. Stimulation of the vagus nerve poses the risk enhanced propensity for development of gastric or duodenal ulcers.
- One objective of the present invention is the selective stimulation of said afferent neural fibers that innervate gastric tissue. Avoidance of vagus nerve stimulation is an object of this modulator configuration.
- Other alternative approaches to gastric pacing involving gastric muscle stimulation secondarily cause stimulation of the vagus nerve as well as stimulation of gastric tissues in acid-secreting regions, consequently posing the undesirable side effects of gastric and duodenal ulcers secondary to activation of gastric acid stimulation.
- This invention includes stimulation of the sympathetic fibers at sites including the zones of innervation of the stomach, the gastric innervation zones excluding those innervated by vagus branches, the distal sympathetic branches proximal to the stomach, the sympathetic trunk, the intermediolateral nucleus, the locus ceruleus, the hypothalamus, and other structures comprising or influencing sympathetic afferent activity.
- Stimulation of the sympathetic afferent fibers elicits the perception of satiety, and achievement of chronic, safe, and efficacious modulation of sympathetic afferents is one of the major objectives of the present invention.
- Alternating and augmenting stimulation of the sympathetic nervous system and vagus nerve is included in the present invention.
- By alternating stimulation of the vagus nerve and the sympathetic afferent fibers one may induce the sensation of satiety in the implanted patient while minimizing the potential risk for gastric and duodenal ulcers.
- vagus and sympathetic afferent fibers carry information that is related to gastric distention
- a major objective of the present invention is the optimization stimulation of the biggest fibers, the afferent sympathetic nervous system fibers, and other afferent pathways such that a maximal sensation of satiety is perceived in the implanted individual and such that habituation of this sensation of satiety is minimized.
- This optimization is performed in any combination of matters including temporal patterning of the individual signals to each neural pathway, including but not limited to the vagus nerve and sympathetic afferents, as well as temporal patterning between a multiplicity of stimulation channels involving the same were neural pathways
- the present invention teaches a multiplicity of apparatus and method for stimulation of afferent sympathetic fibers, as detailed below.
- Other techniques and apparatus may become apparent to those skilled in the art, without departing from the present invention.
- FIG. 1 through FIG. 3 demonstrate stimulation of gastric tissue, including at least one of neural and muscular tissue.
- Anatomical structures include esophagus 15 , lower esophageal sphincter 14 , stomach 8 , cardiac notch of stomach 16 , gastric fundus 9 , greater curvature of stomach 10 , pyloric antrum 11 , lesser curvature of stomach 17 , pylorus 12 , and duodenum 13 .
- Implantable pulse generator 1 is shown with modulator 2 and modulator 3 in contact with the corresponding portion of stomach 8 in the respective figures, detailed below.
- Implantable pulse generator further comprises attachment fixture 4 and attachment fixture 5 . Additional or fewer attachment fixtures may be included without departing from the present invention.
- Attachment means 6 and attachment means 7 are used to secure attachment fixture 4 and attachment fixture 5 , respectively to appropriate portion of stomach 8 .
- Attachment means 6 and attachment means 7 may be comprised from surgical suture material, surgical staples, adhesives, or other means without departing from the present invention.
- FIGS. 1 , 2 , and 3 show implantable pulse generator 1 in several anatomical positions.
- implantable pulse generator 1 is shown positioned along the superior region of the greater curvature of stomach 10 , with modulator 2 and modulator 3 in contact with the tissues comprising the greater curvature of stomach 10 .
- FIG. 2 implantable pulse generator 1 is shown positioned along the inferior region of the greater curvature of stomach 10 , with modulator 2 and modulator 3 in contact with the tissues comprising the greater curvature of stomach 10 .
- implantable pulse generator 1 is shown positioned along the pyloric antrum 11 , with modulator 2 and modulator 3 in contact with the tissues comprising the pyloric antrum 11 .
- Modulator 2 and modulator 3 are used to stimulate at least one of gastric longitudinal muscle layer, gastric circular muscle layer, gastric nervous tissue, or other tissue.
- Modulator 2 and modulator 3 may be fabricated from nonpenetrating material or from penetrating material, including needle tips, arrays of needle tips, wires, conductive sutures, other conductive material, or other material, without departing from the present invention.
- the present invention teaches apparatus and method for stimulation of sympathetic afferent fibers using stimulation in the region of the sympathetic trunk.
- sympathetic trunk neuromodulatory interface 83 and 85 positioned on right sympathetic trunk 71
- sympathetic trunk neuromodulatory interface 85 , 86 positioned on left sympathetic trunk 72 are used to provide stimulation for afferent as well as for efferent sympathetic nervous system modulation. Modulation of efferent sympathetic nervous system is discussed below, and this is used for metabolic modulation.
- the present invention teaches apparatus and method for stimulation of sympathetic afferent fibers using stimulation of nerves arising from the sympathetic trunk.
- thoracic splanchnic neuromodulatory interface 87 , 89 , 88 , and 90 positioned on right greater splanchnic nerve 73 , right lesser splanchnic nerve 75 , left greater splanchnic nerve 74 , left lesser splanchnic nerve 76 , respectively, and are used to provide stimulation for afferent as well as for efferent sympathetic nervous system modulation. Modulation of efferent sympathetic nervous system is discussed below, and this is used for metabolic modulation.
- a further object of the present invention is the stimulation of the gastric musculature.
- This may be performed using either or both of closed loop and open loop control.
- closed loop and open loop control In the present embodiment, a combination of open and closed loop control is employed.
- the open loop control provides a baseline level of gastric stimulation. This stimulation maintains tone of the gastric musculature. This increases the wall tension the stomach and plays a role in the perception of satiety in the implanted patient.
- stimulation of the gastric musculature causes contraction of the structures, thereby reducing the volume of the stomach. This gastric muscle contraction, and the consequent reduction of stomach volume effectively restricts the amount of food that may be ingested.
- Surgical techniques have been developed and are known to those practicing in the field of surgical treatment of obesity.
- the present invention teaches a technique which employs neural modulation and gastric muscle stimulation which by its nature is the variable and reversible. This offers the advantages postoperative adjustment of magnitude, fine tuning for the individual patient, varying of magnitude to suit the patient's changing needs and changing anatomy over time, and the potential for reversal or termination of treatment. Furthermore, since the gastric wall tension is generated in a physiological manner by the muscle itself, it does not have the substantial risk of gastric wall necrosis and rupture inherent in externally applied pressure, as is the case with gastric banding.
- FIGS. 1 , 2 , and 3 depict placements of the implantable pulse generator 1 that may be used to stimulate gastric muscle tissue. Stimulation of both longitudinal and circular muscle layers is included in the present invention. Stimulation of gastric circular muscle layer causes circumferential contraction of the stomach, and stimulation of gastric longitudinal muscle layer causes longitudinal contraction of the stomach.
- This muscle stimulation and contraction accomplishes several objectives: (1) functional reduction in stomach volume, (2) increase in stomach wall tension, (3) reduction in rate of food bolus flow. All of these effects are performed to induce the sensation of satiety.
- FIG. 4 depicts implantable pulse generator 1 positioned to perform stimulation of the gastric pylorus 12 to induce satiety by restricting outflow of food bolus material from the stomach 8 into the duodenum 13 .
- Stimulation of the pylorus 12 may be continuous, intermittent, or triggered manually or by sensed event or physiological condition.
- FIG. 4 depicts implantable pulse generator 1 positioned adjacent to the gastric pylorus 12 ; this position provides secure modulator positioning while eliminating the risk of modulator and wire breakage inherent in other designs in which implantable pulse generator 1 is positioned remote from the gastric pylorus 12 .
- FIG. 5 depicts implantable pulse generator 1 positioned to perform stimulation of the gastric pylorus 12 to induce satiety by restricting outflow of food bolus material from the stomach 8 into the duodenum 13 .
- Stimulation of the pylorus 12 may be continuous, intermittent, or triggered manually or by sensed event or physiological condition.
- FIG. 5 depicts implantable pulse generator 1 attached to stomach 8 , specifically by the pyloric antrum 11 ; this position facilitates the use of a larger implantable pulse generator 1 .
- the risk of modulator and wire breakage is minimized by the use of appropriate strain relief and stranded wire designs.
- the parasympathetic nervous system is complementary to the sympathetic nervous system and plays a substantial role in controlling digestion and cardiac activity.
- Several routes are described in the present invention to modulate activity of the parasympathetic nervous system.
- vagus nerve stimulation for the treatment of a number of disorders including obesity.
- Zabara and others have described systems in which the vagus nerve in the region of the neck is stimulated. This is plagued with a host of problems, including life-threatening cardiac complications as well as difficulties with speech and discomfort during stimulation.
- the present invention is a substantial advance over that discussed by Zabara et al, in which unrestricted fiber activation using epineural stimulation is described. That technique results in indiscriminate stimulation of efferent and afferent fibers. With vagus nerve stimulation, efferent fiber activation generates many undesirable side effects, including gastric and duodenal ulcers, cardiac disturbances, and others.
- vagus neuromodulatory interface 97 and 98 are implanted adjacent to and in communication with right vagus nerve 95 and left vagus nerve 96 .
- the neuromodulatory interface 97 and 98 overcomes these limitations that have persisted for over a decade with indiscriminate vagus nerve stimulation, by selectively stimulating afferent fibers of the at least one of the vagus nerve, the sympathetic nerves, and other nerves.
- the present invention includes the selective stimulation of afferent fibers using a technique in which electrical stimulation is used to block anterograde propagation of action potentials along the efferent fibers.
- the present invention includes the selective stimulation of afferent fibers using a technique in which stimulation is performed proximal to a nerve transection and in which the viability of the afferent fibers is maintained.
- One such implementation involves use of at least one of neuromodulatory interface 34 which is of the form shown in at least one of Longitudinal Electrode Neuromodulatory Interface 118 , Longitudinal Electrode Regeneration Port Neuromodulatory Interface 119 , Regeneration Tube Neuromodulatory Interface 120 , or other design in which a subset of the neuronal population is modulated.
- FIG. 6 depicts multimodal treatment for the generation of satiety, using sympathetic stimulation, gastric muscle stimulation, gastric pylorus stimulation, and vagus nerve stimulation. This is described in more detail below.
- Modulators 30 and 31 are positioned in the general region of the lesser curvature of stomach 17 . Stimulation in this region results in activation of vagus nerve afferent fibers. Stimulation of other regions may be performed without departing from the present invention. In this manner, selective afferent vagus nerve stimulation may be achieved, without the detrimental effects inherent in efferent vagus nerve stimulation, including cardiac rhythm disruption and induction of gastric ulcers.
- the present invention further includes devices designed specifically for the stimulation of afferent fibers.
- FIG. 7 depicts epineural cuff electrode neuromodulatory interface 117 , one of several designs for neuromodulatory interface 34 included in the present invention.
- Nerve 35 is shown inserted through nerve cuff 36 .
- the nerve 35 is transected distal to the epineural cuff electrode neuromodulatory interface 117 .
- This case is depicted here, in which transected nerve end 37 is seen distal to epineural cuff electrode neuromodulatory interface 117 .
- Epineural electrode 49 , 50 , and 51 are mounted along the inner surface of nerve cuff 36 and in contact or close proximity to nerve 35 .
- Epineural electrode connecting wire 52 , 53 , 54 are electrically connected on one end to epineural electrode 49 , 50 , and 51 , respectively, and merge together on the other end to form connecting cable 55 .
- FIG. 8 depicts longitudinal electrode neuromodulatory interface 118 , one of several designs for neuromodulatory interface 34 included in the present invention.
- Nerve 35 is shown inserted into nerve cuff 36 .
- the nerve 35 is transected prior to surgical insertion into nerve cuff 36 .
- Longitudinal electrode array 38 is mounted within nerve cuff 36 and in contact or close proximity to nerve 35 .
- Connecting wire array 40 provides electrical connection from each element of longitudinal electrode array 38 to connecting cable 55 .
- Nerve cuff end plate 41 is attached to the distal end of nerve cuff 36 .
- Nerve 35 may be advanced sufficiently far into longitudinal electrode array 38 such that elements of longitudinal electrode array 38 penetrate into nerve 35 .
- nerve 35 may be placed with a gap between transected nerve end 37 and longitudinal electrode array 38 such that neural regeneration occurs from transected nerve end 37 toward and in close proximity to elements of longitudinal electrode array 38 .
- FIG. 9 depicts longitudinal electrode regeneration port neuromodulatory interface 119 , an improved design for neuromodulatory interface 34 included in the present invention.
- Nerve 35 is shown inserted into nerve cuff 36 .
- the nerve 35 is transected prior to surgical insertion into nerve cuff 36 .
- Longitudinal electrode array 38 is mounted within nerve cuff 36 and in contact or close proximity to nerve 35 .
- Connecting wire array 40 provides electrical connection from each element of longitudinal electrode array 38 to connecting cable 55 .
- Nerve cuff end plate 41 is attached to the distal end of nerve cuff 36 .
- Nerve 35 may be advanced sufficiently far into longitudinal electrode array 38 such that elements of longitudinal electrode array 38 penetrate into nerve 35 .
- nerve 35 may be placed with a gap between transected nerve end 37 and longitudinal electrode array 38 such that neural regeneration occurs from transected nerve end 37 toward and in close proximity to elements of longitudinal electrode array 38 .
- At least one of nerve cuff 36 and nerve cuff end plate 41 are perforated with one or a multiplicity of regeneration port 39 to facilitate and enhance regeneration of nerve fibers from transected nerve end 37 .
- FIG. 10 depicts regeneration tube neuromodulatory interface 120 , an advanced design for neuromodulatory interface 34 included in the present invention.
- Nerve 35 is shown inserted into nerve cuff 36 .
- Regeneration electrode array 44 is mounted within regeneration tube array 42 , which is contained within nerve cuff 36 .
- Each regeneration tube 43 contains at least one element of regeneration electrode array 44 .
- Each element of regeneration electrode array 44 is electrically connected by at least one element of connecting wire array 40 to connecting cable 55 .
- Nerve 35 may be surgically inserted into nerve cuff 36 sufficiently far to be adjacent to regeneration tube array 42 or may be placed with a gap between transected nerve end 37 and regeneration tube array 42 . Neural regeneration occurs from transected nerve end 37 toward and through regeneration tube 43 elements regeneration tube array 42 .
- the present invention further includes stimulation of other tissues that influence vagus nerve activity.
- This method and the associated apparatus facilitates the stimulation of vagus nerve afferent fibers without activating vagus nerve efferent fibers, thereby overcoming the ulcerogenic and cardiac side effects of nonselective vagus nerve stimulation. This represents a major advance in vagus nerve modulation and overcomes the potentially life-threatening complications of nonselective stimulation of the vagus nerve.
- the present invention teaches stimulation of the cervical nerves or their roots or branches for modulation of the parasympathetic nervous system. Additionally, the present invention teaches stimulation of the sacral nerves or their roots or branches for modulation of the parasympathetic nervous system.
- FIG. 6 depicts apparatus and method for performing multichannel modulation of satiety.
- Implantable pulse generator 1 is attached to stomach 8 , via attachment means 6 and 7 connected from stomach 8 to attachment fixture 4 and 5 , respectively.
- Implantable pulse generator 1 is electrically connected via modulator cable 32 to modulators 24 , 25 , 26 , 27 , 28 , and 29 , which are affixed to the stomach 8 preferably along the region of the greater curvature of stomach 10 .
- Implantable pulse generator 1 is additionally electrically connected via modulator cable 33 to modulators 30 and 31 , which are affixed to the stomach 8 preferably along the region of the lesser curvature of stomach 17 .
- Implantable pulse generator 1 is furthermore electrically connected via modulator cable 18 and 19 to modulators 2 and 3 , respectively, which are affixed to the gastric pylorus 12 .
- Modulator 2 is affixed to gastric pylorus via modulator attachment fixture 22 and 23
- modulator 3 is affixed to gastric pylorus via modulator attachment fixture 20 and 21 .
- a multiplicity of modulators including modulator 30 and 31 facilitate stimulation of vagus and sympathetic afferent fibers directly, as well as through stimulation of tissues, including gastric muscle, that in turn influence activity of the sympathetic and vagus afferent fibers.
- any of these modulators may be used to modulate vagus nerve activity; however, one advancement taught in the present invention is the selective stimulation of sympathetic nerve fiber activation, and this is facilitated by modulators 24 , 25 , 26 , 27 , 28 , and 29 , by virtue of their design for and anatomical placement in regions of the stomach 8 that are not innervated by the vagus nerve or its branches.
- the present invention further includes satiety modulation performed with the apparatus depicted in FIG. 16 , and described previously, using stimulation of right sympathetic trunk 71 , left sympathetic trunk 72 , right greater splanchnic nerve 73 , left greater splanchnic nerve 74 , right lesser splanchnic nerve 75 , left lesser splanchnic nerve 76 or other branch or the sympathetic nervous system.
- the present invention includes a multiplicity of potential modulator configurations and combinations of thereof.
- the present embodiment includes modulators placed at a combination of sites to interface with the sympathetic efferent fibers. These sites include the musculature of the stomach, the distal sympathetic branches penetrating into the stomach, postganglionic axons and cell bodies, preganglionic axons and cell bodies, the sympathetic chain and portions thereof, the intermediolateral nucleus, the locus ceruleus, the hypothalamus, and other structures comprising or influencing activity of the sympathetic nervous system.
- Stimulation of the sympathetic efferents is performed to elevate the metabolic rate and lipolysis in the adipose tissue, thereby enhancing breakdown of fat and weight loss in the patient.
- FIGS. 14 , 15 , and 16 depict apparatus for stimulation of the sympathetic nervous system.
- FIG. 14 depicts a subset of anatomical locations for placement of neuromodulatory interfaces for modulation of the sympathetic nervous system.
- FIG. 15 depicts the same apparatus with the further addition of a set of implantable pulse generator 1 and connecting cables.
- FIG. 16 depicts the apparatus shown in FIG. 15 with the further addition of gastric modulation apparatus also depicted in FIG. 6 .
- FIG. 13 reveals the normal anatomy of the thoracic region.
- Trachea 63 is seen posterior to aortic arch 57 .
- Brachiocephalic artery 59 left common carotid artery 60 arise from aortic arch 57
- left subclavian artery 61 arises from the left common carotid artery 60 .
- Right mainstem bronchus 64 and left mainstem bronchus 65 arise from trachea 63 .
- Thoracic descending aorta 58 extends from aortic arch 57 and is continuous with abdominal aorta 62 .
- Right vagus nerve 95 and left vagus nerve 96 are shown.
- Intercostal nerve 69 and 70 are shown between respective pairs of ribs, of which rib 67 and rib 68 are labeled.
- Right sympathetic trunk 71 and left sympathetic trunk are lateral to mediastinum 82 .
- Right greater splanchnic nerve 73 and right lesser splanchnic nerve 75 arise from right sympathetic trunk 71 .
- Left greater splanchnic nerve 74 and left lesser splanchnic nerve 76 arise from left sympathetic trunk 72 .
- Right subdiaphragmatic greater splanchnic nerve 78 , left subdiaphragmatic greater splanchnic nerve 79 , right subdiaphragmatic lesser splanchnic nerve 80 , and left subdiaphragmatic lesser splanchnic nerve 81 are extensions below the diaphragm 77 of the right greater splanchnic nerve 73 , left greater splanchnic nerve 74 , right lesser splanchnic nerve 75 , and left lesser splanchnic nerve 76 , respectively.
- FIG. 14 depicts multichannel sympathetic modulation implanted with relevant anatomical structures.
- Sympathetic trunk neuromodulatory interface 83 and 85 are implanted adjacent to and in communication with right sympathetic trunk 71 .
- Sympathetic trunk neuromodulatory interface 84 and 86 are implanted adjacent to and in communication with left sympathetic trunk 72 .
- Sympathetic trunk neuromodulatory interface 83 , 84 , 85 , and 86 are implanted superior to their respective sympathetic trunk levels at which the right greater splanchnic nerve 73 , left greater splanchnic nerve 74 , right lesser splanchnic nerve 75 , and left lesser splanchnic nerve 76 , arise, respectively.
- Thoracic splanchnic nerve interface 87 , 88 , 89 , 90 are implanted adjacent to and in communication with the right greater splanchnic nerve 73 , left greater splanchnic nerve 74 , right lesser splanchnic nerve 75 , and left lesser splanchnic nerve 76 , arise, respectively.
- Abdominal splanchnic nerve interface 91 , 92 , 93 , and 94 are implanted adjacent to and in communication with the right subdiaphragmatic greater splanchnic nerve 78 , left subdiaphragmatic greater splanchnic nerve 79 , right subdiaphragmatic lesser splanchnic nerve 80 , and left subdiaphragmatic lesser splanchnic nerve 81 , respectively.
- FIG. 15 depicts the implanted neuromodulatory interfaces as in FIG. 14 , with the addition of the implanted pulse generators.
- Implantable pulse generator 99 is connected via connecting cable 103 , 105 , 107 , 109 , 115 , to sympathetic trunk neuromodulatory interface 83 and 85 , and thoracic splanchnic neuromodulatory interface 87 and 89 , and vagus neuromodulatory interface 97 , respectively.
- Implantable pulse generator 100 is connected via connecting cable 104 , 106 , 108 , 110 , 116 , to sympathetic trunk neuromodulatory interface 83 and 85 , and thoracic splanchnic neuromodulatory interface 88 and 90 , and vagus neuromodulatory interface 98 , respectively.
- Implantable pulse generator 101 is connected via connecting cable 111 and 113 to abdominal splanchnic neuromodulatory interface 91 and 93 , respectively.
- Implantable pulse generator 102 is connected via connecting cable 112 and 114 to abdominal splanchnic neuromodulatory interface 92 and 94 , respectively.
- FIGS. 17 and 18 depicts the normal cross sectional anatomy of the spinal cord 151 and anatomy with implanted neuromodulatory interfaces, respectively.
- FIG. 17 depicts the normal anatomical structures of the spinal cord 151 , including several of its component structures such as the intermediolateral nucleus 121 , ventral horn of spinal gray matter 141 , dorsal horn of spinal gray matter 142 , spinal cord white matter 122 , anterior median fissure 123 .
- ventral spinal root 124 dorsal spinal root 125 , spinal ganglion 126 , spinal nerve 127 , spinal nerve anterior ramus 128 , spinal nerve posterior ramus 129 , gray ramus communicantes 130 , white ramus communicantes 131 , sympathetic trunk 132 , pia mater 133 , subarachnoid space 134 , arachnoid 135 , meningeal layer of dura mater 136 , epidural space 137 , periosteal layer of dura mater 138 , and vertebral spinous process 139 , and vertebral facet 140 .
- FIG. 17 depicts the normal anatomy of the spinal cord seen in transverse section.
- Spinal cord and related neural structures include intermediolateral nucleus 121 , spinal cord white matter 122 , anterior median fissure 123 , ventral spinal root 124 , dorsal spinal root 125 , spinal ganglion 126 , spinal nerve 127 , spinal nerve anterior ramus 128 , spinal nerve posterior ramus 129 , gray ramus communicantes 130 , white ramus communicantes 131 , sympathetic trunk 132 , pia mater 133 , subarachnoid space 134 , arachnoid 135 , meningeal layer of dura 136 , epidural space 137 , periosteal layer of dura mater 138 , vertebral spinous process 139 , vertebral facet 140 , ventral horn of spinal gray matter 141 , and dorsal horn of spinal gray matter 142 .
- FIG. 18 depicts the spinal neuromodulatory interfaces positioned in the vicinity of spinal cord 151 .
- Neuromodulatory interfaces positioned anterior to spinal cord 151 include anterior central spinal neuromodulatory interface 143 , anterior right lateral spinal neuromodulatory interface 144 , and anterior left lateral spinal neuromodulatory interface 145 .
- Neuromodulatory interfaces positioned posterior to spinal cord 151 include posterior central spinal neuromodulatory interface 146 , posterior right lateral spinal neuromodulatory interface 147 , and posterior left lateral spinal neuromodulatory interface 148 .
- Neuromodulatory interfaces positioned lateral to spinal cord 151 include right lateral spinal neuromodulatory interface 149 and left lateral spinal neuromodulatory interface 150 .
- Neuromodulatory interfaces positioned within the spinal cord 151 include intermediolateral nucleus neuromodulatory interface 152 .
- Stimulation, inhibition, or other modulation of the spinal cord 151 is used to modulate fibers of the sympathetic nervous system, including those in the intermediolateral nucleus 121 and efferent and efferent fibers connected to the intermediolateral nucleus 121 .
- Modulation of at least one of portions of the spinal cord 151 , intermediolateral nucleus 121 , ventral spinal root 124 , dorsal spinal root 125 , spinal ganglion 126 , spinal nerve 127 , gray ramus communicantes 130 , white ramus communicantes 131 and other structures facilitates modulation of activity of the sympathetic trunk 132 .
- Modulation of activity of the sympathetic trunk 132 is used to modulate at least one of metabolic activity, satiety, and appetite. This may be achieved using intermediolateral nucleus neuromodulatory interface 152 , placed in or adjacent to the intermediolateral nucleus 121 .
- the less invasive design employing neuromodulatory interfaces ( 144 , 145 , 146 , 147 , 148 , 149 , 150 ) shown positioned in the in epidural space 137 is taught in the present invention.
- the present invention further includes modulation of all sympathetic efferent nerves, nerve fibers, and neural structures.
- These sympathetic efferent neural structures include but are not limited to distal sympathetic nerve branches, mesenteric nerves, sympathetic efferent fibers at all spinal levels, rami communicantes at all spinal levels, paravertebral nuclei, prevertebral nuclei, and other sympathetic structures.
- the present invention teaches a device for metabolic control using tactile stimulation.
- Tactile stimulation of afferent neurons causes alterations in activity of sympathetic neurons which influence metabolic activity of adipose tissue.
- the present invention teaches tactile stimulation of skin, dermal and epidermal sensory structures, subcutaneous tissues and structures, and deeper tissues to modulate activity of afferent neurons.
- This device for metabolic control employs vibratory actuators.
- electrical stimulation, mechanical stimulation, optical stimulation, acoustic stimulation, pressure stimulation, and other forms of energy that modulate afferent neural activity are used.
- the preferred embodiment includes a multiplicity of treatment modalities, including afferent, efferent, and neuromuscular modulation.
- Afferent signals are generated to simulate satiety. This is accomplished through neural, neuromuscular, and hydrostatic mechanisms. Electrical stimulation of the vagus via vagus nerve interface 45 afferents provides one such channel to transmit information to the central nervous system for the purpose of eliciting satiety. Electrical stimulation of the sympathetic afferents via sympathetic nerve interface 46 provides another such channel to transmit information to the central nervous system for the purpose of eliciting satiety. Electrical stimulation of gastric circular muscle layer
- multimodal stimulation is depicted, including stimulation of gastric musculature using modulators 2 and 3 , as well as stimulation of afferent fibers of the proximal stump of vagus nerve 47 using vagus nerve modulator 45 and stimulation of afferent fibers of sympathetic nerve branch 48 .
- expanded multimodal stimulation is depicted, including those modalities shown in FIG. 11 , including stimulation of gastric musculature using modulators 2 and 3 , as well as stimulation of afferent fibers of the proximal stump of vagus nerve 47 using vagus nerve modulator 45 and stimulation of afferent fibers of sympathetic nerve branch 48 , in addition to those modalities shown in FIG. 6 , explained in detail above, including modulation of gastric muscular fibers, sympathetic afferent fibers innervating gastric tissues, and vagus afferent fibers innervating gastric tissues.
- FIG. 16 further expanded multimodal modulation is depicted, including modalities encompassed and described above and depicted in FIG. 15 and FIG. 12 .
- Neuromodulatory interfaces that use electrical energy to modulate neural activity may deliver a broad spectrum of electrical waveforms.
- One preferred set of neural stimulation parameter sets includes pulse frequencies ranging from 0.1 Hertz to 1000 Hertz, pulse widths from 1 microsecond to 500 milliseconds. Pulses are charge balanced to insure no net direct current charge delivery.
- the preferred waveform is bipolar pulse pair, with an interpulse interval of 1 microsecond to 1000 milliseconds.
- Current regulated stimulation is preferred and includes pulse current amplitudes ranging from 1 microamp to 1000 milliamps. Alternatively, voltage regulation may be used, and pulse voltage amplitudes ranging from 1 microvolt to 1000 volts.
Abstract
The present invention teaches a method and apparatus for physiological modulation, including neural and gastrointestinal modulation, for the purposes of treating several disorders, including obesity, depression, epilepsy, and diabetes. This includes chronically implanted neural and neuromuscular modulators, used to modulate the afferent neurons of the sympathetic nervous system to induce satiety as well as to modulate the efferent neurons of the sympathetic nervous system to modulate metabolism, including metabolic rate. Furthermore, this includes neuromuscular stimulation of the stomach to effect baseline and intermittent smooth muscle contraction to increase gastric intraluminal pressure, which induces satiety, and stimulate sympathetic afferent fibers, including those in the sympathetic trunk, splanchnic nerves, and greater curvature of the stomach, to augment the perception of satiety.
Description
- This application is a continuation of U.S. patent application Ser. No. 10/198,871 (Docket GISTIM 01.01), entitled METHOD AND APPARATUS FOR NEUROMODULATION AND PHSYIOLOGIC MODULATION FOR THE TREATMENT OF METABOLIC AND NEUROPSYCHIATRIC DISEASE, filed Jul. 19, 2002, and naming as inventor Daniel John DiLorenzo, which is a continuation of U.S. Provisional Patent Application Ser. No. 60/307,124, entitled PHYSIOLOGIC MODULATION FOR THE CONTROL OF OBESITY, DEPRESSION, EPILEPSY, AND DIABETES, filed Jul. 23, 2001, and naming as inventor Daniel John DiLorenzo.
- This application is a continuation of and incorporates by reference U.S. Utility patent application Ser. No. 12/387,638 (Docket GISTIM 01.04), filed May 5, 2009, entitled “Methods and Apparatus for Neuromodulation and Physiologic Modulation for the Treatment of Obesity and Metabolic and Neuropsychiatric Disease” and naming as inventor Daniel John DiLorenzo.
- This application is a continuation of and incorporates by reference U.S. Provisional Patent Application No. 60/500,911, filed Sep. 5, 2003 and naming as inventor Daniel John DiLorenzo.
- This application incorporates by reference U.S. Provisional Patent Application No. 60/579,074, filed Jun. 10, 2004 and naming as inventor Daniel John DiLorenzo.
- This application incorporates by reference U.S. patent application Ser. No. 10/008,576, entitled OPTIMAL METHOD AND APPARATUS FOR NEURAL MODULATION FOR THE TREATMENT OF NEUROLOGICAL DISEASE, PARTICULARLY MOVEMENT DISORDERS, filed Nov. 11, 2001, and naming as inventor Daniel John DiLorenzo; which is a continuation of U.S. patent application Ser. No. 09/340,326, entitled APPARATUS AND METHOD FOR CLOSED-LOOP INTRACRANIAL STIMULATION FOR OPTIMAL CONTROL OF NEUROLOGICAL DISEASE, filed Jun. 25, 1999, and naming as inventor Daniel John DiLorenzo; which claims the benefit of U.S. Provisional Patent Application Ser. No. 60/095,413 entitled OPTIMAL METHOD AND APPARATUS FOR NEURAL MODULATION FOR THE TREATMENT OF NEUROLOGICAL DISEASE, PARTICULARLY MOVEMENT DISORDERS, filed Aug. 5, 1998 and naming as inventor Daniel John DiLorenzo.
- This application incorporates by reference U.S. Provisional Application Ser. No. 60/427,699, entitled APPARATUS AND METHOD FOR CLOSED-LOOP INTRACRANIAL SIMULATION FOR OPTIMAL CONTROL OF NEUROLOGICAL DISEASE, filed Nov. 20, 2002, and naming as inventor Daniel John DiLorenzo.
- This application incorporates by reference U.S. Provisional Application Ser. No. 60/436,792, entitled APPARATUS AND METHOD FOR CLOSED-LOOP INTRACRANIAL STIMULATION FOR OPTIMAL CONTROL OF NEUROLOGICAL DISEASE, filed Dec. 27, 2002, and naming as inventor Daniel John DiLorenzo.
- This application incorporates by reference U.S. Provisional Application Ser. No. 60/438,286, entitled ADAPTIVE CLOSED-LOOP NEUROMODULATION SYSTEM, filed Jan. 6, 2003, and naming as inventor Daniel John DiLorenzo.
- This application incorporates by reference U.S. Provisional Application Ser. No. 60/460,140 filed Apr. 3, 2003.
- All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
- 1. Field of the Invention
- The present invention relates generally to metabolic disease and neuropsychiatric disease and, more particularly, to stimulation of gastric and sympathetic neural tissue for the treatment of obesity and depression.
- 2. Related Art
- Physiologic studies have demonstrated the presence of a sympathetic nervous system afferent pathway transmitting gastric distention information to the hypothalamus. [Barone, Zarco de Coronado et al. (1995). Gastric distension modulates hypothalamic neurons via a sympathetic afferent path through the mesencephalic periaqueductal gray. Brain Research Bulletin. 38: 239-51.] However, prior techniques have generally not addressed the problems associated with satiety, morbidity, mortality of intracranial modulation and the risk of ulcers. Unlike prior techniques, by specifically targeting sympathetic afferent fibers, the present invention effects the sensation of satiety and avoids the substantial risks of morbidity and mortality of intracranial modulation, particularly dangerous in the vicinity of the hypothalamus. Furthermore, this invention avoids the risk of ulcers inherent in vagus nerve stimulation.
- Stimulation of intracranial structures has been proposed and described for the treatment of obesity (U.S. Pat. No. 5,782,798). Stimulation of the left ventromedial hypothalamic (VMH) nucleus resulted in delayed eating by dogs who had been food deprived. Following 24 hours of food deprivation, dogs with VMH stimulation waited between 1 and 18 hours after food presentation before consuming a meal. Sham control dogs ate immediately upon food presentation. Dogs that received 1 hour of stimulation every 12 hours for 3 consecutive days maintained an average daily food intake of 35% of normal baseline levels. [Brown, Fessler et al. (1984). Changes in food intake with electrical stimulation of the ventromedial hypothalamus in dogs. Journal of Neurosurgery. 60: 1253-7.]
- B. Candidate Peripheral Nerve Path ways for Modulating Satiety
- The effect of gastric distension on activity in the lateral hypothalamus-lateral preoptic area-medial forebrain bundle (LPA-LH-MFB) was studied to determine the pathways for this gastric afferent input to the hypothalamus. [Barone, Zarco de Coronado et al. (1995). Gastric distension modulates hypothalamic neurons via a sympathetic afferent path through the mesencephalic periaqueductal gray. Brain Research Bulletin. 38: 239-51.] The periaqueductal gray matter (PAG) was found to be a relay station for this information. [Barone, Zarco de Coronado et al. (1995). Gastric distension modulates hypothalamic neurons via a sympathetic afferent path through the mesencephalic periaqueductal gray. Brain Research Bulletin. 38: 239-51.] This modulation of the hypothalamus was attenuated but not permanently eliminated by bilateral transection of the vagus nerve. This modulation was, however, significantly reduced or eliminated by bilateral transection of the cervical sympathetic chain or spinal transection at the first cervical level. [Barone, Zarco de Coronado et al. (1995). Gastric distension modulates hypothalamic neurons via a sympathetic afferent path through the mesencephalic periaqueductal gray. Brain Research Bulletin. 38: 239-51.] These signals containing gastric distension and temperature stimulation are mediated to a large degree by sympathetic afferents, and the PAG is a relay station for this gastric afferent input to the hypothalamus. [Barone, Zarco de Coronado et al. (1995). Gastric distension modulates hypothalamic neurons via a sympathetic afferent path through the mesencephalic periaqueductal gray. Brain Research Bulletin. 38: 239-51.]
- For example, in the LPA-LH-MFB study, 26.1% of the 245 neurons studied were affected by gastric stimulation, with 17.6% increasing in firing frequency and 8.6% decreasing during gastric distension. [Barone, Zarco de Coronado et al. (1995). Gastric distension modulates hypothalamic neurons via a sympathetic afferent path through the mesencephalic periaqueductal gray. Brain Research Bulletin. 38: 239-51.] The response of 8 of 8 neurons sensitive to gastric distension were maintained, though attenuated after bilateral vagus nerves were cut. In 2 of these 8 cells, the effect was transiently eliminated for 2-4 minutes after left vagus transection, and then activity recovered. In 3 LH-MFB cells, two increased and the other decreased firing rate with gastric distension. Following bilateral sympathetic ganglion transection, the response of two were eliminated, and the third (which increased firing with distension) had a significantly attenuated response. [Barone, Zarco de Coronado et al. (1995). Gastric distension modulates hypothalamic neurons via a sympathetic afferent path through the mesencephalic periaqueductal gray. Brain Research Bulletin. 38: 239-51.] Vagus stimulation resulted in opposite or similar responses as gastric distension on the mesencephalic cells
- Gastric vagal input to neurons throughout the hypothalamus has been characterized. [Yuan and Barber (1992). Hypothalamic unitary responses to gastric vagal input from the proximal stomach. American Journal of Physiology. 262: G74-80.] Nonselective epineural vagus nerve stimulation (VNS) has been described for the treatment of Obesity (U.S. Pat. No. 5,188,104). This suffers from several significant limitations that are overcome by the present invention.
- The vagus nerve is well known to mediate gastric hydrochloric acid secretion. Dissection of the vagus nerve off the stomach is often performed as part of major gastric surgery for ulcers. Stimulation of the vagus nerve may pose risks for ulcers in patients, of particular concern, as obese patients often have gastroesophageal reflux disease (GERD); further augmentation of gastric acid secretion would only exacerbate this condition.
- The present invention teaches a significantly more advanced neuroelectric interface technology to stimulate the vagus nerve and avoid the efferent vagus side effects, including speech and cardiac side effects common in with existing VNS technology as well as the potential ulcerogenic side effects. However, since sympathetic afferent activity appears more responsive to gastric distension, this may represent a stronger channel for modulating satiety. Furthermore, by pacing stimulating modulators on the greater curvature of the stomach, one may stimulate the majority of the circular layer of gastric musculature, thereby diffusely increasing gastric tone.
- The muscular layer of the stomach is comprised of 3 layers: (1) an outer longitudinal layer, (2) a circular layer in between, and (3) a deeper oblique layer. [Gray (1974). Gray's Anatomy. T. Pick and R. Howden. Philadelphia, Running Press.] The circular fibers, which lie deep to the superficial longitudinal fibers, would appear to be the layer of choice for creating uniform and consistent gastric contraction with elevated wall tension and luminal pressure. Therefore, modulators should have the ability to deliver stimulation through the longitudinal layer. If the modulator is in the form of an electrode, then the electrodes should have the ability to deliver current through the longitudinal layer.
- Gray's Anatomy describes innervation as including the right and left pneumogastric nerves (not the vagus nerves), being distributed on the back and front of the stomach, respectively. A great number of branches from the sympathetic nervous system also supply the stomach. [Gray (1974). Gray's Anatomy. T. Pick and R. Howden. Philadelphia, Running Press.]
- Electrical stimulation of the VMH enhances lipogenesis in the brown adipose tissue (BAT), preferentially over the white adipose tissue (WAT) and liver, probably through a mechanism involving activation of the sympathetic innervation of the BAT. [Takahashi and Shimazu (1982). Hypothalamic regulation of lipid metabolism in the rat: effect of hypothalamic stimulation on lipogenesis. Journal of the Autonomic Nervous System. 6: 225-35.]
- The VMH is a hypothalamic component of the sympathetic nervous system. [Ban (1975). Fiber connections in the hypothalamus and some autonomic functions. Pharmacology Biochemistry & Behavior. 3: 3-13.]
- A thermogenic response in BAT was observed with direct sympathetic nerve stimulation. [Flaim, Horwitz et al. (1977). Coupling of signals to brown fat: α- and β-adrenergic responses in intact rats. Amer. J. Physiol. 232: R101-R109.] The BAT had abundant sympathetic innervation with adrenergic fibers that form nest-like networks around every fat cell, [Derry, Schonabum et al. (1969). Two sympathetic nerve supplies to brown adipose tissue of the rat. Canad. J. Physiol. Pharmacol. 47: 57-63.] whereas WAT has no adrenergic fibers in direct contact with fat cells except those related to the blood vessels. [Daniel and Derry (1969). Criteria for differentiation of brown and white fat in the rat. Canad. J. Physiol. Pharmacol. 47: 941-945.]
- The present invention teaches apparatus and methods for treating a multiplicity of diseases, including obesity, depression, epilepsy, diabetes, and other diseases. The invention taught herein employs a variety of energy modalities to modulate central nervous system structures, peripheral nervous system structures, and peripheral tissues and to modulate physiology of neural structures and other organs, including gastrointestinal, adipose, pancreatic, and other tissues. The methods for performing this modulation, including the sites of stimulation and the modulator configurations are described. The apparatus for performing the stimulation are also described. This invention teaches a combination of novel anatomic approaches and apparatus designs for direct and indirect modulation of the autonomic nervous system, which is comprised of the sympathetic nervous system and the parasympathetic nervous system.
- For the purposes of this description the term GastroPace should be interpreted to mean the devices constituting the system of the present embodiment of this invention.
- The present invention teaches several mechanisms, including neural modulation and direct contraction of the gastric musculature, to effect the perception of satiety. This modulation is useful in the treatment of obesity and eating disorders, including anorexia nervosa and bulimia.
- Direct stimulation of the gastric musculature increases the intraluminal pressure within the stomach; and this simulates the physiologic condition of having a full stomach, sensed by stretch receptors in the muscle tissue and transmitted via neural afferent pathways to the hypothalamus and other central nervous system structures, where the neural activity is perceived as satiety.
- This may be accomplished with the several alternative devices and methods taught in the present invention. Stimulation of any of the gastric fundus, greater curvature of stomach, pyloric antrum, or lesser curvature of stomach, or other region of the stomach or gastrointestinal tract, increases the intraluminal pressure. Increase of intraluminal pressure physiologically resembles fullness of the respective organ, and satiety is perceived.
- The present invention also includes the restriction of the flow of food to effect satiety. This is accomplished by stimulation of the pylorus. The pylorus is the sphincter-like muscle at the distal juncture of the stomach with the duodenum, and it regulates food outflow from the stomach into the duodenum. By stimulating contraction of the pylorus, food outflow from the stomach is slowed or delayed. The presence of a volume of food in the stomach distends the gastric musculature and causes the person to experience satiety.
- An association has been made between depression and overeating, particularly with the craving of carbohydrates; and is believed to be an association between the sense of satiety and relief of depression. Stimulation of the gastric tissues, in a manner that resembles or is perceived as satiety, as described above, provides relief from this craving and thereby relief from some depressive symptoms.
- There are several mechanisms, including those taught above for the treatment of obesity that are applicable to the treatment of depression, anxiety, and other neuropsychiatric conditions
- The present invention includes electrical stimulation of peripheral nervous system and other structures and tissues to modulate the activity in the central nervous system to control seizure activity.
- This modulation takes the form of peripheral nervous system stimulation using a multiplicity of novel techniques and apparatus. Direct stimulation of peripheral nerves is taught; this includes stimulation of the vagus, trigeminal, accessory, and sympathetic nerves. Indiscriminate stimulation of the vagus nerves has been described for some disorders, but the limitations in this technique are substantial, including cardiac rhythm disruptions, speech difficulties, and gastric and duodenal ulcers. The present invention overcomes these persistent limitations by teaching a method and apparatus for the selective stimulation of structures, including the vagus nerve as well as other peripheral nerves, and other neural, neuromuscular, and other tissues.
- The present invention further includes noninvasive techniques for neural modulation. This includes the use of tactile stimulation to activate peripheral or cranial nerves. This noninvasive stimulation includes the use of tactile stimulation, including light touch, pressure, vibration, and other modalities that may be used to activate the peripheral or cranial nerves. Temperature stimulation, including hot and cold, as well as constant or variable temperatures, are included in the present invention.
- The response of the gastrointestinal system, including the pancreas, to a meal includes several phases. The first phase, the anticipatory stage, is neurally mediated. Prior to the actual consumption of a meal, saliva production increases and the gastrointestinal system prepares for the digestion of the food to be ingested. Innervation of the pancreas, in an analogous manner, controls production of insulin.
- Modulation of pancreatic production of insulin may be performed by modulation of at least one of afferent or efferent neural structures. Afferent modulation of at least one of the vagus nerve, the sympathetic structures innervating the gastrointestinal tissue, the sympathetic trunk, and the gastrointestinal tissues themselves is used as an input signal to influence central and peripheral nervous system control of insulin secretion.
-
FIG. 1 depicts GastroPace implanted along the Superior Greater Curvature of the stomach for both Neural Afferent and Neuromuscular Modulation -
FIG. 2 depicts GastroPace implanted along the Inferior Greater Curvature of the stomach for both Neural Afferent and Neuromuscular Modulation -
FIG. 3 depicts GastroPace implanted along the Pyloric Antrum of the stomach for both Neural Afferent and Neuromuscular Modulation -
FIG. 4 depicts GastroPace implanted adjacent to the Gastric Pylorus for modulation of pylorus activity and consequent control of gastric food efflux and intraluminal pressure -
FIG. 5 depicts GastroPace implanted along the Pyloric Antrum of the stomach with modulators positioned for stimulation of Neural and Neuromuscular structures of the Pylorus and Pyloric Antrum of the Stomach -
FIG. 6 depicts GastroPace implanted along the Pyloric Antrum of the stomach with modulators positioned for stimulation of Neural and Neuromuscular structures of the Pylorus, Pyloric Antrum, Greater Curvature, and Lesser Curvature of the Stomach -
FIG. 7 depicts the Nerve Cuff Electrode, comprising the Epineural Electrode Nerve Cuff Design -
FIG. 8 depicts the Nerve Cuff Electrode, comprising the Axial Electrode Blind End Port Design -
FIG. 9 depicts the Nerve Cuff Electrode, comprising the Axial Electrode Regeneration Port Design -
FIG. 10 depicts the Nerve Cuff Electrode, comprising the Axial Regeneration Tube Design -
FIG. 11 depicts GastroPace implanted along the Pyloric Antrum of the stomach with modulators positioned for stimulation of Afferent Neural Structures, including sympathetic and parasympathetic fibers -
FIG. 12 depicts GastroPace implanted along the Pyloric Antrum of the stomach with modulators positioned for stimulation of Neural and Neuromuscular structures of the Pylorus, Pyloric Antrum, Greater Curvature, and Lesser Curvature of the Stomach and with modulators positioned for stimulation of Afferent Neural Structures, including sympathetic and parasympathetic fibers -
FIG. 13 depicts the Normal Thoracoabdominal anatomy as seen via a sagittal view of an open dissection -
FIG. 14 depicts modulators for GastroPace positioned on the sympathetic trunk and on the greater and lesser splanchnic nerves, both supradiaphragmatically and infradiaphragmatically, for afferent and efferent neural modulation. -
FIG. 15 depicts GastroPace configured with multiple pulse generators, their connecting cables, and multiple modulators positioned on the sympathetic trunk and on the greater and lesser splanchnic nerves, both supradiaphragmatically and infradiaphragmatically, for afferent and efferent neural modulation. -
FIG. 16 depicts GastroPace configured with multiple pulse generators, their connecting cables, and multiple modulators positioned on the sympathetic trunk and on the greater and lesser splanchnic nerves, both supradiaphragmatically and infradiaphragmatically, for afferent and efferent neural modulation and with modulators positioned for stimulation of Neural and Neuromuscular structures of the Pylorus, Pyloric Antrum, Greater Curvature, and Lesser Curvature of the Stomach -
FIG. 17 depicts the Normal Spinal Cord Anatomy, shown in Transverse SectionFIG. 18 depicts GastroPace implanted with multiple modulators positioned for modulation of Spinal Cord structures - The present invention encompasses a multimodal technique, method, and apparatus for the treatment of several diseases, including but not limited to obesity, eating disorders, depression, epilepsy, and diabetes.
- These modalities may be used for diagnostic and therapeutic uses, and these modalities include but are not limited to stimulation of gastric tissue, stimulation of gastric musculature, stimulation of gastric neural tissue, stimulation of sympathetic nervous tissue, stimulation of parasympathetic nervous tissue, stimulation of peripheral nervous tissue, stimulation of central nervous tissue, stimulation of cranial nervous tissue, stimulation of skin receptors, including Pacinian corpuscles, nociceptors, golgi tendons, and other sensory tissues in the skin, subcutaneous tissue, muscles, and joints.
- Stimulation may be accomplished by electrical means, optical means, electromagnetic means, radiofrequency means, electrostatic means, magnetic means, vibrotactile means, pressure means, pharmacologic means, chemical means, electrolytic concentration means, thermal means, or other means for altering tissue activity.
- Already encompassed in the above description are several specific applications of this broad technology. These specific applications include electrical stimulation of gastric tissue, including at least one of muscle and neural, for the control of appetite and satiety, and for the treatment of obesity. Additional specific uses include electrical stimulation of gastric tissue for the treatment of depression. Further uses include electrical stimulation of pancreatic tissue for the treatment of diabetes
- Selected stimulation of the sympathetic nervous system is an objective of the present invention. A variety of modulator designs and configurations are included in the present invention and other designs and configurations may be apparent to those skilled in the art and these are also included in the present invention. Said modulator may take the form of electrode or electrical source, optical source, electromagnetic source, radiofrequency source, electrostatic source, magnetic source, vibrotactile source, pressure source, pharmacologic source, chemical source, electrolyte source, thermal source, or other energy or stimulus source.
- One objective of the modulator design for selective sympathetic nervous system stimulation is the avoidance of stimulation of the vagus nerve. Stimulation of the vagus nerve poses the risk enhanced propensity for development of gastric or duodenal ulcers.
- Other techniques in which electrical stimulation has been used for the treatment of obesity have included stimulation of central nervous system structures or peripheral nervous system structures. Other techniques have used sequential stimulation of the gastric tissue to interrupt peristalsis; however, this broad stimulation of gastric tissue necessarily overlaps regions heavily innervated by the vagus nerve and consequently poses the same risks of gastric and duodenal ulcers that stimulation of the vagus nerve does.
- One objective of the present invention is the selective stimulation of said afferent neural fibers that innervate gastric tissue. Avoidance of vagus nerve stimulation is an object of this modulator configuration. Other alternative approaches to gastric pacing involving gastric muscle stimulation secondarily cause stimulation of the vagus nerve as well as stimulation of gastric tissues in acid-secreting regions, consequently posing the undesirable side effects of gastric and duodenal ulcers secondary to activation of gastric acid stimulation.
- There are a number of approaches to selective stimulation of the sympathetic nervous system. This invention includes stimulation of the sympathetic fibers at sites including the zones of innervation of the stomach, the gastric innervation zones excluding those innervated by vagus branches, the distal sympathetic branches proximal to the stomach, the sympathetic trunk, the intermediolateral nucleus, the locus ceruleus, the hypothalamus, and other structures comprising or influencing sympathetic afferent activity.
- Stimulation of the sympathetic afferent fibers elicits the perception of satiety, and achievement of chronic, safe, and efficacious modulation of sympathetic afferents is one of the major objectives of the present invention.
- Alternating and augmenting stimulation of the sympathetic nervous system and vagus nerve is included in the present invention. By alternating stimulation of the vagus nerve and the sympathetic afferent fibers, one may induce the sensation of satiety in the implanted patient while minimizing the potential risk for gastric and duodenal ulcers.
- Since vagus and sympathetic afferent fibers carry information that is related to gastric distention, a major objective of the present invention is the optimization stimulation of the biggest fibers, the afferent sympathetic nervous system fibers, and other afferent pathways such that a maximal sensation of satiety is perceived in the implanted individual and such that habituation of this sensation of satiety is minimized. This optimization is performed in any combination of matters including temporal patterning of the individual signals to each neural pathway, including but not limited to the vagus nerve and sympathetic afferents, as well as temporal patterning between a multiplicity of stimulation channels involving the same were neural pathways
- The present invention teaches a multiplicity of apparatus and method for stimulation of afferent sympathetic fibers, as detailed below. Other techniques and apparatus may become apparent to those skilled in the art, without departing from the present invention.
- A1a. Sympathetic Afferents—Gastric Region
-
FIG. 1 throughFIG. 3 demonstrate stimulation of gastric tissue, including at least one of neural and muscular tissue. Anatomical structures includeesophagus 15, loweresophageal sphincter 14,stomach 8, cardiac notch ofstomach 16,gastric fundus 9, greater curvature ofstomach 10,pyloric antrum 11, lesser curvature ofstomach 17,pylorus 12, andduodenum 13. -
Implantable pulse generator 1 is shown withmodulator 2 andmodulator 3 in contact with the corresponding portion ofstomach 8 in the respective figures, detailed below. Implantable pulse generator further comprisesattachment fixture 4 andattachment fixture 5. Additional or fewer attachment fixtures may be included without departing from the present invention. Attachment means 6 and attachment means 7 are used to secureattachment fixture 4 andattachment fixture 5, respectively to appropriate portion ofstomach 8. Attachment means 6 and attachment means 7 may be comprised from surgical suture material, surgical staples, adhesives, or other means without departing from the present invention. - FIGS. 1,2, and 3 show
implantable pulse generator 1 in several anatomical positions. InFIG. 1 ,implantable pulse generator 1 is shown positioned along the superior region of the greater curvature ofstomach 10, withmodulator 2 andmodulator 3 in contact with the tissues comprising the greater curvature ofstomach 10. InFIG. 2 ,implantable pulse generator 1 is shown positioned along the inferior region of the greater curvature ofstomach 10, withmodulator 2 andmodulator 3 in contact with the tissues comprising the greater curvature ofstomach 10. InFIG. 3 ,implantable pulse generator 1 is shown positioned along thepyloric antrum 11, withmodulator 2 andmodulator 3 in contact with the tissues comprising thepyloric antrum 11. -
Modulator 2 andmodulator 3 are used to stimulate at least one of gastric longitudinal muscle layer, gastric circular muscle layer, gastric nervous tissue, or other tissue.Modulator 2 andmodulator 3 may be fabricated from nonpenetrating material or from penetrating material, including needle tips, arrays of needle tips, wires, conductive sutures, other conductive material, or other material, without departing from the present invention. - A1b. Sympathetic Afferents—Sympathetic Trunk
- The present invention teaches apparatus and method for stimulation of sympathetic afferent fibers using stimulation in the region of the sympathetic trunk. As shown in
FIGS. 14 , 15, and 16, sympathetictrunk neuromodulatory interface sympathetic trunk 71, and sympathetictrunk neuromodulatory interface sympathetic trunk 72, are used to provide stimulation for afferent as well as for efferent sympathetic nervous system modulation. Modulation of efferent sympathetic nervous system is discussed below, and this is used for metabolic modulation. - A1e. Sympathetic Afferents—Other
- The present invention teaches apparatus and method for stimulation of sympathetic afferent fibers using stimulation of nerves arising from the sympathetic trunk. As shown in
FIGS. 14 , 15, and 16, thoracicsplanchnic neuromodulatory interface splanchnic nerve 73, right lessersplanchnic nerve 75, left greatersplanchnic nerve 74, left lessersplanchnic nerve 76, respectively, and are used to provide stimulation for afferent as well as for efferent sympathetic nervous system modulation. Modulation of efferent sympathetic nervous system is discussed below, and this is used for metabolic modulation. - A further object of the present invention is the stimulation of the gastric musculature. This may be performed using either or both of closed loop and open loop control. In the present embodiment, a combination of open and closed loop control is employed. The open loop control provides a baseline level of gastric stimulation. This stimulation maintains tone of the gastric musculature. This increases the wall tension the stomach and plays a role in the perception of satiety in the implanted patient. Additionally, stimulation of the gastric musculature causes contraction of the structures, thereby reducing the volume of the stomach. This gastric muscle contraction, and the consequent reduction of stomach volume effectively restricts the amount of food that may be ingested. Surgical techniques have been developed and are known to those practicing in the field of surgical treatment of obesity. Several of these procedures are of the restrictive type, but because of their surgical nature they are fixed in magnitude and difficult if not impossible to reverse. The present invention teaches a technique which employs neural modulation and gastric muscle stimulation which by its nature is the variable and reversible. This offers the advantages postoperative adjustment of magnitude, fine tuning for the individual patient, varying of magnitude to suit the patient's changing needs and changing anatomy over time, and the potential for reversal or termination of treatment. Furthermore, since the gastric wall tension is generated in a physiological manner by the muscle itself, it does not have the substantial risk of gastric wall necrosis and rupture inherent in externally applied pressure, as is the case with gastric banding.
-
FIGS. 1 , 2, and 3 depict placements of theimplantable pulse generator 1 that may be used to stimulate gastric muscle tissue. Stimulation of both longitudinal and circular muscle layers is included in the present invention. Stimulation of gastric circular muscle layer causes circumferential contraction of the stomach, and stimulation of gastric longitudinal muscle layer causes longitudinal contraction of the stomach. - This muscle stimulation and contraction accomplishes several objectives: (1) functional reduction in stomach volume, (2) increase in stomach wall tension, (3) reduction in rate of food bolus flow. All of these effects are performed to induce the sensation of satiety.
-
FIG. 4 depictsimplantable pulse generator 1 positioned to perform stimulation of thegastric pylorus 12 to induce satiety by restricting outflow of food bolus material from thestomach 8 into theduodenum 13. Stimulation of the pylorus 12 may be continuous, intermittent, or triggered manually or by sensed event or physiological condition.FIG. 4 depictsimplantable pulse generator 1 positioned adjacent to thegastric pylorus 12; this position provides secure modulator positioning while eliminating the risk of modulator and wire breakage inherent in other designs in whichimplantable pulse generator 1 is positioned remote from thegastric pylorus 12. -
FIG. 5 depictsimplantable pulse generator 1 positioned to perform stimulation of thegastric pylorus 12 to induce satiety by restricting outflow of food bolus material from thestomach 8 into theduodenum 13. Stimulation of the pylorus 12 may be continuous, intermittent, or triggered manually or by sensed event or physiological condition.FIG. 5 depictsimplantable pulse generator 1 attached tostomach 8, specifically by thepyloric antrum 11; this position facilitates the use of a largerimplantable pulse generator 1. The risk of modulator and wire breakage is minimized by the use of appropriate strain relief and stranded wire designs. - The parasympathetic nervous system is complementary to the sympathetic nervous system and plays a substantial role in controlling digestion and cardiac activity. Several routes are described in the present invention to modulate activity of the parasympathetic nervous system.
- A4a. Parasympathetic Stimulation—Vagus Nerve
- Others have advocated the use of vagus nerve stimulation for the treatment of a number of disorders including obesity. Zabara and others have described systems in which the vagus nerve in the region of the neck is stimulated. This is plagued with a host of problems, including life-threatening cardiac complications as well as difficulties with speech and discomfort during stimulation. The present invention is a substantial advance over that discussed by Zabara et al, in which unrestricted fiber activation using epineural stimulation is described. That technique results in indiscriminate stimulation of efferent and afferent fibers. With vagus nerve stimulation, efferent fiber activation generates many undesirable side effects, including gastric and duodenal ulcers, cardiac disturbances, and others.
- In the present invention, as depicted in
FIG. 14 ,vagus neuromodulatory interface right vagus nerve 95 and leftvagus nerve 96. Theneuromodulatory interface neuromodulatory interface 34 which is of the form shown in at least one of LongitudinalElectrode Neuromodulatory Interface 118, Longitudinal Electrode RegenerationPort Neuromodulatory Interface 119, RegenerationTube Neuromodulatory Interface 120, or other design in which a subset of the neuronal population is modulated. - A.4.a.i. Innovative Stimulation Anatomy
-
FIG. 6 depicts multimodal treatment for the generation of satiety, using sympathetic stimulation, gastric muscle stimulation, gastric pylorus stimulation, and vagus nerve stimulation. This is described in more detail below.Modulators stomach 17. Stimulation in this region results in activation of vagus nerve afferent fibers. Stimulation of other regions may be performed without departing from the present invention. In this manner, selective afferent vagus nerve stimulation may be achieved, without the detrimental effects inherent in efferent vagus nerve stimulation, including cardiac rhythm disruption and induction of gastric ulcers. - The present invention further includes devices designed specifically for the stimulation of afferent fibers.
-
FIG. 7 depicts epineural cuffelectrode neuromodulatory interface 117, one of several designs forneuromodulatory interface 34 included in the present invention.Nerve 35 is shown inserted throughnerve cuff 36. For selective afferent stimulation, thenerve 35 is transected distal to the epineural cuffelectrode neuromodulatory interface 117. This case is depicted here, in which transectednerve end 37 is seen distal to epineural cuffelectrode neuromodulatory interface 117.Epineural electrode nerve cuff 36 and in contact or close proximity tonerve 35. Epineuralelectrode connecting wire epineural electrode cable 55. -
FIG. 8 depicts longitudinalelectrode neuromodulatory interface 118, one of several designs forneuromodulatory interface 34 included in the present invention.Nerve 35 is shown inserted intonerve cuff 36. For selective afferent stimulation, thenerve 35 is transected prior to surgical insertion intonerve cuff 36.Longitudinal electrode array 38 is mounted withinnerve cuff 36 and in contact or close proximity tonerve 35.Connecting wire array 40 provides electrical connection from each element oflongitudinal electrode array 38 to connectingcable 55. Nervecuff end plate 41 is attached to the distal end ofnerve cuff 36.Nerve 35 may be advanced sufficiently far intolongitudinal electrode array 38 such that elements oflongitudinal electrode array 38 penetrate intonerve 35. Alternatively,nerve 35 may be placed with a gap between transectednerve end 37 andlongitudinal electrode array 38 such that neural regeneration occurs from transectednerve end 37 toward and in close proximity to elements oflongitudinal electrode array 38. -
FIG. 9 depicts longitudinal electrode regenerationport neuromodulatory interface 119, an improved design forneuromodulatory interface 34 included in the present invention.Nerve 35 is shown inserted intonerve cuff 36. For selective afferent stimulation, thenerve 35 is transected prior to surgical insertion intonerve cuff 36.Longitudinal electrode array 38 is mounted withinnerve cuff 36 and in contact or close proximity tonerve 35.Connecting wire array 40 provides electrical connection from each element oflongitudinal electrode array 38 to connectingcable 55. Nervecuff end plate 41 is attached to the distal end ofnerve cuff 36.Nerve 35 may be advanced sufficiently far intolongitudinal electrode array 38 such that elements oflongitudinal electrode array 38 penetrate intonerve 35. Alternatively,nerve 35 may be placed with a gap between transectednerve end 37 andlongitudinal electrode array 38 such that neural regeneration occurs from transectednerve end 37 toward and in close proximity to elements oflongitudinal electrode array 38. At least one ofnerve cuff 36 and nervecuff end plate 41 are perforated with one or a multiplicity ofregeneration port 39 to facilitate and enhance regeneration of nerve fibers from transectednerve end 37. -
FIG. 10 depicts regenerationtube neuromodulatory interface 120, an advanced design forneuromodulatory interface 34 included in the present invention.Nerve 35 is shown inserted intonerve cuff 36. For selective afferent stimulation, thenerve 35 is transected prior to surgical insertion intonerve cuff 36.Regeneration electrode array 44 is mounted withinregeneration tube array 42, which is contained withinnerve cuff 36. Eachregeneration tube 43 contains at least one element ofregeneration electrode array 44. Each element ofregeneration electrode array 44 is electrically connected by at least one element of connectingwire array 40 to connectingcable 55.Nerve 35 may be surgically inserted intonerve cuff 36 sufficiently far to be adjacent toregeneration tube array 42 or may be placed with a gap between transectednerve end 37 andregeneration tube array 42. Neural regeneration occurs from transectednerve end 37 toward and throughregeneration tube 43 elementsregeneration tube array 42. - The present invention further includes stimulation of other tissues that influence vagus nerve activity. These include tissues of the esophagus, stomach, small and large intestine, pancreas, liver, gallbladder, kidney, mesentery, appendix, bladder, uterus, and other intraabdominal tissues. Stimulation of one or a multiplicity of these tissues modulates activity of the vagus nerve afferent fibers without significantly altering activity of efferent fibers. This method and the associated apparatus facilitates the stimulation of vagus nerve afferent fibers without activating vagus nerve efferent fibers, thereby overcoming the ulcerogenic and cardiac side effects of nonselective vagus nerve stimulation. This represents a major advance in vagus nerve modulation and overcomes the potentially life-threatening complications of nonselective stimulation of the vagus nerve.
- A4b. Parasympathetic Stimulation—Other
- The present invention teaches stimulation of the cervical nerves or their roots or branches for modulation of the parasympathetic nervous system. Additionally, the present invention teaches stimulation of the sacral nerves or their roots or branches for modulation of the parasympathetic nervous system.
-
FIG. 6 depicts apparatus and method for performing multichannel modulation of satiety.Implantable pulse generator 1 is attached tostomach 8, via attachment means 6 and 7 connected fromstomach 8 toattachment fixture Implantable pulse generator 1 is electrically connected viamodulator cable 32 tomodulators stomach 8 preferably along the region of the greater curvature ofstomach 10.Implantable pulse generator 1 is additionally electrically connected viamodulator cable 33 to modulators 30 and 31, which are affixed to thestomach 8 preferably along the region of the lesser curvature ofstomach 17.Implantable pulse generator 1 is furthermore electrically connected viamodulator cable modulators gastric pylorus 12.Modulator 2 is affixed to gastric pylorus via modulator attachment fixture 22 and 23, andmodulator 3 is affixed to gastric pylorus viamodulator attachment fixture - Using the apparatus depicted in
FIG. 6 , satiety modulation is achieved through multiple modalities. A multiplicity of modulators, includingmodulator modulator modulators stomach 8 that are not innervated by the vagus nerve or its branches. - In addition to the apparatus and methods depicted in
FIG. 6 for satiety modulation, the present invention further includes satiety modulation performed with the apparatus depicted inFIG. 16 , and described previously, using stimulation of rightsympathetic trunk 71, leftsympathetic trunk 72, right greatersplanchnic nerve 73, left greatersplanchnic nerve 74, right lessersplanchnic nerve 75, left lessersplanchnic nerve 76 or other branch or the sympathetic nervous system. - One objective of the modulator configuration employed in the present invention is the selected stimulation of sympathetic efferent nerve fibers. The present invention includes a multiplicity of potential modulator configurations and combinations of thereof. The present embodiment includes modulators placed at a combination of sites to interface with the sympathetic efferent fibers. These sites include the musculature of the stomach, the distal sympathetic branches penetrating into the stomach, postganglionic axons and cell bodies, preganglionic axons and cell bodies, the sympathetic chain and portions thereof, the intermediolateral nucleus, the locus ceruleus, the hypothalamus, and other structures comprising or influencing activity of the sympathetic nervous system.
- Stimulation of the sympathetic efferents is performed to elevate the metabolic rate and lipolysis in the adipose tissue, thereby enhancing breakdown of fat and weight loss in the patient.
- B.1.a. Sympathetic Efferent Stimulation—Sympathetic Trunk
-
FIGS. 14 , 15, and 16 depict apparatus for stimulation of the sympathetic nervous system.FIG. 14 depicts a subset of anatomical locations for placement of neuromodulatory interfaces for modulation of the sympathetic nervous system.FIG. 15 depicts the same apparatus with the further addition of a set ofimplantable pulse generator 1 and connecting cables.FIG. 16 depicts the apparatus shown inFIG. 15 with the further addition of gastric modulation apparatus also depicted inFIG. 6 . -
FIG. 13 reveals the normal anatomy of the thoracic region.Trachea 63 is seen posterior toaortic arch 57.Brachiocephalic artery 59, left commoncarotid artery 60 arise fromaortic arch 57, and leftsubclavian artery 61 arises from the left commoncarotid artery 60.Right mainstem bronchus 64 and leftmainstem bronchus 65 arise fromtrachea 63. Thoracic descendingaorta 58 extends fromaortic arch 57 and is continuous withabdominal aorta 62.Right vagus nerve 95 and leftvagus nerve 96 are shown.Intercostal nerve rib 67 andrib 68 are labeled. - Right
sympathetic trunk 71 and left sympathetic trunk are lateral to mediastinum 82. Right greatersplanchnic nerve 73 and right lessersplanchnic nerve 75 arise from rightsympathetic trunk 71. Left greatersplanchnic nerve 74 and left lessersplanchnic nerve 76 arise from leftsympathetic trunk 72. Right subdiaphragmatic greatersplanchnic nerve 78, left subdiaphragmatic greatersplanchnic nerve 79, right subdiaphragmatic lessersplanchnic nerve 80, and left subdiaphragmatic lessersplanchnic nerve 81 are extensions below thediaphragm 77 of the right greatersplanchnic nerve 73, left greatersplanchnic nerve 74, right lessersplanchnic nerve 75, and left lessersplanchnic nerve 76, respectively. - B.1.b. Sympathetic Efferent Stimulation—Splanchnics
-
FIG. 14 depicts multichannel sympathetic modulation implanted with relevant anatomical structures. Sympathetictrunk neuromodulatory interface sympathetic trunk 71. Sympathetictrunk neuromodulatory interface sympathetic trunk 72. Sympathetictrunk neuromodulatory interface splanchnic nerve 73, left greatersplanchnic nerve 74, right lessersplanchnic nerve 75, and left lessersplanchnic nerve 76, arise, respectively. - Thoracic
splanchnic nerve interface splanchnic nerve 73, left greatersplanchnic nerve 74, right lessersplanchnic nerve 75, and left lessersplanchnic nerve 76, arise, respectively. Abdominalsplanchnic nerve interface splanchnic nerve 78, left subdiaphragmatic greatersplanchnic nerve 79, right subdiaphragmatic lessersplanchnic nerve 80, and left subdiaphragmatic lessersplanchnic nerve 81, respectively. - Stimulation of at least one of right
sympathetic trunk 71, leftsympathetic trunk 72, right greatersplanchnic nerve 73, left greatersplanchnic nerve 74, right lessersplanchnic nerve 75, and left lessersplanchnic nerve 76, right subdiaphragmatic greatersplanchnic nerve 78, left subdiaphragmatic greatersplanchnic nerve 79, right subdiaphragmatic lessersplanchnic nerve 80, and left subdiaphragmatic lessersplanchnic nerve 81 enhances metabolism of adipose tissue. Stimulation of these structures may be performed using at least one of electrical energy, electrical fields, optical energy, mechanical energy, magnetic energy, chemical compounds, pharmacological compounds, thermal energy, vibratory energy, or other means for modulating neural activity. -
FIG. 15 depicts the implanted neuromodulatory interfaces as inFIG. 14 , with the addition of the implanted pulse generators.Implantable pulse generator 99 is connected via connectingcable trunk neuromodulatory interface splanchnic neuromodulatory interface vagus neuromodulatory interface 97, respectively.Implantable pulse generator 100 is connected via connectingcable trunk neuromodulatory interface splanchnic neuromodulatory interface vagus neuromodulatory interface 98, respectively.Implantable pulse generator 101 is connected via connectingcable splanchnic neuromodulatory interface Implantable pulse generator 102 is connected via connectingcable splanchnic neuromodulatory interface - B.1.c. Sympathetic Efferent Stimulation—Spinal Cord
-
FIGS. 17 and 18 depicts the normal cross sectional anatomy of thespinal cord 151 and anatomy with implanted neuromodulatory interfaces, respectively. -
FIG. 17 depicts the normal anatomical structures of thespinal cord 151, including several of its component structures such as theintermediolateral nucleus 121, ventral horn of spinalgray matter 141, dorsal horn of spinalgray matter 142, spinal cordwhite matter 122, anteriormedian fissure 123. Other structures adjacent to or surroundingspinal cord 151 include ventralspinal root 124, dorsalspinal root 125,spinal ganglion 126,spinal nerve 127, spinal nerveanterior ramus 128, spinal nerveposterior ramus 129, gray ramus communicantes 130,white ramus communicantes 131,sympathetic trunk 132, pia mater 133,subarachnoid space 134, arachnoid 135, meningeal layer ofdura mater 136,epidural space 137, periosteal layer ofdura mater 138, and vertebralspinous process 139, and vertebral facet 140. -
FIG. 17 depicts the normal anatomy of the spinal cord seen in transverse section. Spinal cord and related neural structures includeintermediolateral nucleus 121, spinal cordwhite matter 122, anteriormedian fissure 123, ventralspinal root 124, dorsalspinal root 125,spinal ganglion 126,spinal nerve 127, spinal nerveanterior ramus 128, spinal nerveposterior ramus 129, gray ramus communicantes 130,white ramus communicantes 131,sympathetic trunk 132, pia mater 133,subarachnoid space 134, arachnoid 135, meningeal layer ofdura 136,epidural space 137, periosteal layer ofdura mater 138, vertebralspinous process 139, vertebral facet 140, ventral horn of spinalgray matter 141, and dorsal horn of spinalgray matter 142. -
FIG. 18 depicts the spinal neuromodulatory interfaces positioned in the vicinity ofspinal cord 151. Neuromodulatory interfaces positioned anterior tospinal cord 151 include anterior centralspinal neuromodulatory interface 143, anterior right lateralspinal neuromodulatory interface 144, and anterior left lateralspinal neuromodulatory interface 145. Neuromodulatory interfaces positioned posterior tospinal cord 151 include posterior centralspinal neuromodulatory interface 146, posterior right lateralspinal neuromodulatory interface 147, and posterior left lateralspinal neuromodulatory interface 148. Neuromodulatory interfaces positioned lateral tospinal cord 151 include right lateralspinal neuromodulatory interface 149 and left lateralspinal neuromodulatory interface 150. Neuromodulatory interfaces positioned within thespinal cord 151 include intermediolateralnucleus neuromodulatory interface 152. - Stimulation, inhibition, or other modulation of the
spinal cord 151 is used to modulate fibers of the sympathetic nervous system, including those in theintermediolateral nucleus 121 and efferent and efferent fibers connected to theintermediolateral nucleus 121. Modulation of at least one of portions of thespinal cord 151,intermediolateral nucleus 121, ventralspinal root 124, dorsalspinal root 125,spinal ganglion 126,spinal nerve 127, gray ramus communicantes 130,white ramus communicantes 131 and other structures facilitates modulation of activity of thesympathetic trunk 132. Modulation of activity of thesympathetic trunk 132, in turn, is used to modulate at least one of metabolic activity, satiety, and appetite. This may be achieved using intermediolateralnucleus neuromodulatory interface 152, placed in or adjacent to theintermediolateral nucleus 121. The less invasive design employing neuromodulatory interfaces (144, 145, 146, 147, 148, 149, 150) shown positioned in the inepidural space 137 is taught in the present invention. - B.1.d. Sympathetic Efferent Stimulation—Other
- The present invention further includes modulation of all sympathetic efferent nerves, nerve fibers, and neural structures. These sympathetic efferent neural structures include but are not limited to distal sympathetic nerve branches, mesenteric nerves, sympathetic efferent fibers at all spinal levels, rami communicantes at all spinal levels, paravertebral nuclei, prevertebral nuclei, and other sympathetic structures.
- The present invention teaches a device for metabolic control using tactile stimulation. Tactile stimulation of afferent neurons causes alterations in activity of sympathetic neurons which influence metabolic activity of adipose tissue. The present invention teaches tactile stimulation of skin, dermal and epidermal sensory structures, subcutaneous tissues and structures, and deeper tissues to modulate activity of afferent neurons.
- This device for metabolic control employs vibratory actuators. Alternatively, electrical stimulation, mechanical stimulation, optical stimulation, acoustic stimulation, pressure stimulation, and other forms of energy that modulate afferent neural activity, are used.
- To maximize efficacy while tailoring treatment to minimize side effects, the preferred embodiment includes a multiplicity of treatment modalities, including afferent, efferent, and neuromuscular modulation.
- Afferent signals are generated to simulate satiety. This is accomplished through neural, neuromuscular, and hydrostatic mechanisms. Electrical stimulation of the vagus via
vagus nerve interface 45 afferents provides one such channel to transmit information to the central nervous system for the purpose of eliciting satiety. Electrical stimulation of the sympathetic afferents viasympathetic nerve interface 46 provides another such channel to transmit information to the central nervous system for the purpose of eliciting satiety. Electrical stimulation of gastric circular muscle layer - In
FIG. 11 , multimodal stimulation is depicted, including stimulation of gastricmusculature using modulators vagus nerve 47 usingvagus nerve modulator 45 and stimulation of afferent fibers ofsympathetic nerve branch 48. - In
FIG. 12 , expanded multimodal stimulation is depicted, including those modalities shown inFIG. 11 , including stimulation of gastricmusculature using modulators vagus nerve 47 usingvagus nerve modulator 45 and stimulation of afferent fibers ofsympathetic nerve branch 48, in addition to those modalities shown inFIG. 6 , explained in detail above, including modulation of gastric muscular fibers, sympathetic afferent fibers innervating gastric tissues, and vagus afferent fibers innervating gastric tissues. - In
FIG. 16 , further expanded multimodal modulation is depicted, including modalities encompassed and described above and depicted inFIG. 15 andFIG. 12 . This includes modulation of gastric muscle fibers, fibers of thesympathetic nerve branch 48 andvagus nerve 47 that innervate gastric tissues, and a multiplicity of structures in the sympathetic nervous system andvagus nerve 47. - Neuromodulatory interfaces that use electrical energy to modulate neural activity may deliver a broad spectrum of electrical waveforms. One preferred set of neural stimulation parameter sets includes pulse frequencies ranging from 0.1 Hertz to 1000 Hertz, pulse widths from 1 microsecond to 500 milliseconds. Pulses are charge balanced to insure no net direct current charge delivery. The preferred waveform is bipolar pulse pair, with an interpulse interval of 1 microsecond to 1000 milliseconds. Current regulated stimulation is preferred and includes pulse current amplitudes ranging from 1 microamp to 1000 milliamps. Alternatively, voltage regulation may be used, and pulse voltage amplitudes ranging from 1 microvolt to 1000 volts. These parameters are provided as exemplary of some of the ranges included in the present invention; variations from these parameter sets are included in the present invention.
Claims (20)
1. A device for treating disease, comprising:
(A) an implantable pulse generator, comprising a processor configured to generate a signal which modulates the spinal neurons to induce weight loss;
(B) a conducting member attached to said implantable pulse generator; and
(C) a modulator, wherein said modulator comprises a spinal neuromodulatory interface connected to said implantable pulse generator via said conducting member and which delivers reversible modulation to neurons of the sympathetic nervous system.
2. The device for treating disease as in claim 1 wherein said modulator is in communication with intermediolateral neurons.
3. The device for treating disease as in claim 1 wherein said modulator is in communication with the intermediolateral nucleus.
4. The device for treating disease as in claim 1 wherein said modulator is in communication with thoracic spinal neurons.
5. The device for treating disease as in claim 1 wherein said modulator is in communication with the abdominal spinal neurons.
6. The device for treating disease as in claim 1 wherein said modulator is configured to modulate neural activity for the treatment of obesity.
7. The device for treating disease as in claim 1 wherein said modulator is configured to modulate neural activity for the control of metabolism.
8. The device for treating disease as in claim 1 wherein said modulator is configured to modulate neural activity for the control of body weight.
9. The device for treating disease as in claim 1 wherein said modulator delivers electrical energy.
10. The device for treating disease as in claim 1 wherein said modulator comprises an anterior central spinal neuromodulatory interface.
11. The device for treating disease as in claim 1 wherein said modulator comprises at least one of an anterior right lateral spinal neuromodulatory interface and an anterior left lateral spinal neuromodulatory interface.
12. The device for treating disease as in claim 1 wherein said modulator comprises a posterior central spinal neuromodulatory interface.
13. The device for treating disease as in claim 1 wherein said modulator comprises at least one of a posterior right lateral spinal neuromodulatory interface and a posterior left lateral spinal neuromodulatory interface.
14. The device for treating disease as in claim 1 wherein said modulator comprises at least one of a right lateral spinal neuromodulatory interface and a left lateral spinal neuromodulatory interface.
15. The device for treating disease as in claim 1 wherein said modulator is configured to deliver energy to afferent neurons.
16. The device for treating disease as in claim 1 wherein said modulator is configured to deliver energy to efferent neurons.
17. The device for treating disease as in claim 1 wherein said modulator is configured to deliver energy to somatosensory neurons.
18. A device for treating a condition in a user, comprising:
(A) a pulse generator, comprising a processor configured to generate a signal which modulates the spinal cord to induce weight loss;
(B) a signal transmitting member, configured to transmit said signal from said pulse generator to a modulator; and
(C) the modulator, wherein said modulator delivers at least one modality of energy to at least a component of the user's sympathetic nervous system.
19. The device as in claim 125, wherein said modulator delivers electrical energy.
20. A device for treating disease, comprising:
(A) an implantable pulse generator, comprising a processor configured to generate at least one signal which modulates spinal neurons to induce weight loss;
(B) a conducting member attached to said implantable pulse generator; and
(C) a modulator, wherein said modulator comprises at least one spinal neuromodulatory interface connected to said implantable pulse generator via said conducting member and which delivers reversible multimodal modulation.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/462,903 US20090306739A1 (en) | 2001-07-23 | 2009-08-09 | Methods and apparatus for neuromodulation and physiologic modulation for the treatment of obesity and metabolic and neuropsychiatric disease |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30712401P | 2001-07-23 | 2001-07-23 | |
US10/198,871 US7599736B2 (en) | 2001-07-23 | 2002-07-19 | Method and apparatus for neuromodulation and physiologic modulation for the treatment of metabolic and neuropsychiatric disease |
US12/387,638 US20090216286A1 (en) | 2001-07-23 | 2009-05-05 | Methods and apparatus for neuromodulation and physiologic modulation for the treatment of obesity and metabolic and neuropsychiatric disease |
US12/462,903 US20090306739A1 (en) | 2001-07-23 | 2009-08-09 | Methods and apparatus for neuromodulation and physiologic modulation for the treatment of obesity and metabolic and neuropsychiatric disease |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/198,871 Continuation US7599736B2 (en) | 1998-08-05 | 2002-07-19 | Method and apparatus for neuromodulation and physiologic modulation for the treatment of metabolic and neuropsychiatric disease |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090306739A1 true US20090306739A1 (en) | 2009-12-10 |
Family
ID=26894226
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/198,871 Expired - Lifetime US7599736B2 (en) | 1998-08-05 | 2002-07-19 | Method and apparatus for neuromodulation and physiologic modulation for the treatment of metabolic and neuropsychiatric disease |
US10/872,549 Expired - Fee Related US7529582B1 (en) | 1998-08-05 | 2004-06-21 | Method and apparatus for neuromodulation and physiologic modulation for the treatment of metabolic and neuropsychiatric disease |
US12/387,638 Abandoned US20090216286A1 (en) | 2001-07-23 | 2009-05-05 | Methods and apparatus for neuromodulation and physiologic modulation for the treatment of obesity and metabolic and neuropsychiatric disease |
US12/462,903 Abandoned US20090306739A1 (en) | 2001-07-23 | 2009-08-09 | Methods and apparatus for neuromodulation and physiologic modulation for the treatment of obesity and metabolic and neuropsychiatric disease |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/198,871 Expired - Lifetime US7599736B2 (en) | 1998-08-05 | 2002-07-19 | Method and apparatus for neuromodulation and physiologic modulation for the treatment of metabolic and neuropsychiatric disease |
US10/872,549 Expired - Fee Related US7529582B1 (en) | 1998-08-05 | 2004-06-21 | Method and apparatus for neuromodulation and physiologic modulation for the treatment of metabolic and neuropsychiatric disease |
US12/387,638 Abandoned US20090216286A1 (en) | 2001-07-23 | 2009-05-05 | Methods and apparatus for neuromodulation and physiologic modulation for the treatment of obesity and metabolic and neuropsychiatric disease |
Country Status (1)
Country | Link |
---|---|
US (4) | US7599736B2 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090254143A1 (en) * | 2008-04-04 | 2009-10-08 | Tweden Katherine S | Methods and systems for glucose regulation |
US7986995B2 (en) | 2003-02-03 | 2011-07-26 | Enteromedics Inc. | Bulimia treatment |
US8103349B2 (en) | 2005-08-17 | 2012-01-24 | Enteromedics Inc. | Neural electrode treatment |
US8825164B2 (en) | 2010-06-11 | 2014-09-02 | Enteromedics Inc. | Neural modulation devices and methods |
US8974445B2 (en) | 2009-01-09 | 2015-03-10 | Recor Medical, Inc. | Methods and apparatus for treatment of cardiac valve insufficiency |
AU2010343059B2 (en) * | 2010-01-22 | 2015-04-02 | Ethicon Endo-Surgery, Inc. | Methods and devices for activating brown adipose tissue using electrical energy |
US9700372B2 (en) | 2002-07-01 | 2017-07-11 | Recor Medical, Inc. | Intraluminal methods of ablating nerve tissue |
US10080884B2 (en) | 2014-12-29 | 2018-09-25 | Ethicon Llc | Methods and devices for activating brown adipose tissue using electrical energy |
US10092738B2 (en) | 2014-12-29 | 2018-10-09 | Ethicon Llc | Methods and devices for inhibiting nerves when activating brown adipose tissue |
US10499937B2 (en) | 2006-05-19 | 2019-12-10 | Recor Medical, Inc. | Ablation device with optimized input power profile and method of using the same |
Families Citing this family (327)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020169485A1 (en) | 1995-10-16 | 2002-11-14 | Neuropace, Inc. | Differential neurostimulation therapy driven by physiological context |
US8321013B2 (en) * | 1996-01-08 | 2012-11-27 | Impulse Dynamics, N.V. | Electrical muscle controller and pacing with hemodynamic enhancement |
US8825152B2 (en) * | 1996-01-08 | 2014-09-02 | Impulse Dynamics, N.V. | Modulation of intracellular calcium concentration using non-excitatory electrical signals applied to the tissue |
US7167748B2 (en) | 1996-01-08 | 2007-01-23 | Impulse Dynamics Nv | Electrical muscle controller |
JP4175662B2 (en) | 1996-01-08 | 2008-11-05 | インパルス ダイナミクス エヌ.ヴイ. | Electric muscle control device |
US9289618B1 (en) | 1996-01-08 | 2016-03-22 | Impulse Dynamics Nv | Electrical muscle controller |
US9713723B2 (en) | 1996-01-11 | 2017-07-25 | Impulse Dynamics Nv | Signal delivery through the right ventricular septum |
US7799337B2 (en) | 1997-07-21 | 2010-09-21 | Levin Bruce H | Method for directed intranasal administration of a composition |
US7599736B2 (en) | 2001-07-23 | 2009-10-06 | Dilorenzo Biomedical, Llc | Method and apparatus for neuromodulation and physiologic modulation for the treatment of metabolic and neuropsychiatric disease |
US7853329B2 (en) | 1998-08-05 | 2010-12-14 | Neurovista Corporation | Monitoring efficacy of neural modulation therapy |
US9415222B2 (en) | 1998-08-05 | 2016-08-16 | Cyberonics, Inc. | Monitoring an epilepsy disease state with a supervisory module |
US9042988B2 (en) | 1998-08-05 | 2015-05-26 | Cyberonics, Inc. | Closed-loop vagus nerve stimulation |
US7974696B1 (en) | 1998-08-05 | 2011-07-05 | Dilorenzo Biomedical, Llc | Closed-loop autonomic neuromodulation for optimal control of neurological and metabolic disease |
US9375573B2 (en) | 1998-08-05 | 2016-06-28 | Cyberonics, Inc. | Systems and methods for monitoring a patient's neurological disease state |
US7277758B2 (en) * | 1998-08-05 | 2007-10-02 | Neurovista Corporation | Methods and systems for predicting future symptomatology in a patient suffering from a neurological or psychiatric disorder |
US7747325B2 (en) * | 1998-08-05 | 2010-06-29 | Neurovista Corporation | Systems and methods for monitoring a patient's neurological disease state |
US7209787B2 (en) * | 1998-08-05 | 2007-04-24 | Bioneuronics Corporation | Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease |
US8762065B2 (en) * | 1998-08-05 | 2014-06-24 | Cyberonics, Inc. | Closed-loop feedback-driven neuromodulation |
US7076307B2 (en) * | 2002-05-09 | 2006-07-11 | Boveja Birinder R | Method and system for modulating the vagus nerve (10th cranial nerve) with electrical pulses using implanted and external components, to provide therapy neurological and neuropsychiatric disorders |
US20040249421A1 (en) * | 2000-09-13 | 2004-12-09 | Impulse Dynamics Nv | Blood glucose level control |
US8346363B2 (en) | 1999-03-05 | 2013-01-01 | Metacure Limited | Blood glucose level control |
US8019421B2 (en) * | 1999-03-05 | 2011-09-13 | Metacure Limited | Blood glucose level control |
US9101765B2 (en) * | 1999-03-05 | 2015-08-11 | Metacure Limited | Non-immediate effects of therapy |
US8666495B2 (en) * | 1999-03-05 | 2014-03-04 | Metacure Limited | Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar |
US8700161B2 (en) * | 1999-03-05 | 2014-04-15 | Metacure Limited | Blood glucose level control |
WO2006073671A1 (en) * | 2004-12-09 | 2006-07-13 | Impulse Dynamics Nv | Protein activity modification |
US20070203531A9 (en) * | 1999-12-03 | 2007-08-30 | Medtronic, Inc. | Heart rate variability control of gastric electrical stimulator |
US6885888B2 (en) * | 2000-01-20 | 2005-04-26 | The Cleveland Clinic Foundation | Electrical stimulation of the sympathetic nerve chain |
JP2003530169A (en) * | 2000-04-11 | 2003-10-14 | ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システム | Electrical stimulation of the gastrointestinal tract |
US8467874B2 (en) * | 2000-04-11 | 2013-06-18 | The Board Of Regents Of The University Of Texas System | Gastrointestinal electrical stimulation |
US8761903B2 (en) * | 2000-10-11 | 2014-06-24 | The Board Of Regents Of The University Of Texas | Gastrointestinal electrical stimulation |
US8914114B2 (en) * | 2000-05-23 | 2014-12-16 | The Feinstein Institute For Medical Research | Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation |
CN1476339A (en) * | 2000-09-26 | 2004-02-18 | 特兰施钮罗尼克斯股份有限公司 | Method and apparatus for treating obesity by electrical stimulation of gastrointestinal tract using sensed activity |
US6907295B2 (en) | 2001-08-31 | 2005-06-14 | Biocontrol Medical Ltd. | Electrode assembly for nerve control |
US20060167498A1 (en) * | 2001-07-23 | 2006-07-27 | Dilorenzo Daniel J | Method, apparatus, and surgical technique for autonomic neuromodulation for the treatment of disease |
US20060116736A1 (en) * | 2001-07-23 | 2006-06-01 | Dilorenzo Daniel J | Method, apparatus, and surgical technique for autonomic neuromodulation for the treatment of obesity |
US20070162085A1 (en) * | 2001-07-23 | 2007-07-12 | Dilorenzo Biomedical, Llc | Method, apparatus, surgical technique, and stimulation parameters for autonomic neuromodulation for the treatment of obesity |
US20090187230A1 (en) * | 2001-07-23 | 2009-07-23 | Dilorenzo Daniel J | Method and apparatus for programming of autonomic neuromodulation for the treatment of obesity |
US7974693B2 (en) | 2001-08-31 | 2011-07-05 | Bio Control Medical (B.C.M.) Ltd. | Techniques for applying, configuring, and coordinating nerve fiber stimulation |
US7904176B2 (en) * | 2006-09-07 | 2011-03-08 | Bio Control Medical (B.C.M.) Ltd. | Techniques for reducing pain associated with nerve stimulation |
US7778711B2 (en) * | 2001-08-31 | 2010-08-17 | Bio Control Medical (B.C.M.) Ltd. | Reduction of heart rate variability by parasympathetic stimulation |
US8571653B2 (en) * | 2001-08-31 | 2013-10-29 | Bio Control Medical (B.C.M.) Ltd. | Nerve stimulation techniques |
US7885709B2 (en) * | 2001-08-31 | 2011-02-08 | Bio Control Medical (B.C.M.) Ltd. | Nerve stimulation for treating disorders |
EP1487494A2 (en) * | 2002-02-26 | 2004-12-22 | North Shore-Long Island Jewish Research Institute | Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors |
US7689276B2 (en) * | 2002-09-13 | 2010-03-30 | Leptos Biomedical, Inc. | Dynamic nerve stimulation for treatment of disorders |
US7689277B2 (en) * | 2002-03-22 | 2010-03-30 | Leptos Biomedical, Inc. | Neural stimulation for treatment of metabolic syndrome and type 2 diabetes |
US7236822B2 (en) * | 2002-03-22 | 2007-06-26 | Leptos Biomedical, Inc. | Wireless electric modulation of sympathetic nervous system |
US20090259279A1 (en) * | 2002-03-22 | 2009-10-15 | Dobak Iii John D | Splanchnic nerve stimulation for treatment of obesity |
US7239912B2 (en) * | 2002-03-22 | 2007-07-03 | Leptos Biomedical, Inc. | Electric modulation of sympathetic nervous system |
US7551964B2 (en) * | 2002-03-22 | 2009-06-23 | Leptos Biomedical, Inc. | Splanchnic nerve stimulation for treatment of obesity |
US7702386B2 (en) * | 2002-03-22 | 2010-04-20 | Leptos Biomedical, Inc. | Nerve stimulation for treatment of obesity, metabolic syndrome, and Type 2 diabetes |
US7937145B2 (en) * | 2002-03-22 | 2011-05-03 | Advanced Neuromodulation Systems, Inc. | Dynamic nerve stimulation employing frequency modulation |
US8145316B2 (en) | 2002-04-08 | 2012-03-27 | Ardian, Inc. | Methods and apparatus for renal neuromodulation |
US9636174B2 (en) | 2002-04-08 | 2017-05-02 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for therapeutic renal neuromodulation |
US9308043B2 (en) | 2002-04-08 | 2016-04-12 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for monopolar renal neuromodulation |
US20070129761A1 (en) | 2002-04-08 | 2007-06-07 | Ardian, Inc. | Methods for treating heart arrhythmia |
US7620451B2 (en) | 2005-12-29 | 2009-11-17 | Ardian, Inc. | Methods and apparatus for pulsed electric field neuromodulation via an intra-to-extravascular approach |
US20110207758A1 (en) * | 2003-04-08 | 2011-08-25 | Medtronic Vascular, Inc. | Methods for Therapeutic Renal Denervation |
US20140018880A1 (en) | 2002-04-08 | 2014-01-16 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for monopolar renal neuromodulation |
US7617005B2 (en) | 2002-04-08 | 2009-11-10 | Ardian, Inc. | Methods and apparatus for thermally-induced renal neuromodulation |
US7756583B2 (en) | 2002-04-08 | 2010-07-13 | Ardian, Inc. | Methods and apparatus for intravascularly-induced neuromodulation |
US8175711B2 (en) | 2002-04-08 | 2012-05-08 | Ardian, Inc. | Methods for treating a condition or disease associated with cardio-renal function |
US6978174B2 (en) * | 2002-04-08 | 2005-12-20 | Ardian, Inc. | Methods and devices for renal nerve blocking |
US7853333B2 (en) | 2002-04-08 | 2010-12-14 | Ardian, Inc. | Methods and apparatus for multi-vessel renal neuromodulation |
US8131371B2 (en) * | 2002-04-08 | 2012-03-06 | Ardian, Inc. | Methods and apparatus for monopolar renal neuromodulation |
US7653438B2 (en) | 2002-04-08 | 2010-01-26 | Ardian, Inc. | Methods and apparatus for renal neuromodulation |
US8145317B2 (en) | 2002-04-08 | 2012-03-27 | Ardian, Inc. | Methods for renal neuromodulation |
US9308044B2 (en) | 2002-04-08 | 2016-04-12 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for therapeutic renal neuromodulation |
US7162303B2 (en) | 2002-04-08 | 2007-01-09 | Ardian, Inc. | Renal nerve stimulation method and apparatus for treatment of patients |
US8774913B2 (en) * | 2002-04-08 | 2014-07-08 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for intravasculary-induced neuromodulation |
US20070135875A1 (en) * | 2002-04-08 | 2007-06-14 | Ardian, Inc. | Methods and apparatus for thermally-induced renal neuromodulation |
US8774922B2 (en) | 2002-04-08 | 2014-07-08 | Medtronic Ardian Luxembourg S.A.R.L. | Catheter apparatuses having expandable balloons for renal neuromodulation and associated systems and methods |
US8347891B2 (en) | 2002-04-08 | 2013-01-08 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and apparatus for performing a non-continuous circumferential treatment of a body lumen |
US20080213331A1 (en) | 2002-04-08 | 2008-09-04 | Ardian, Inc. | Methods and devices for renal nerve blocking |
US8150519B2 (en) | 2002-04-08 | 2012-04-03 | Ardian, Inc. | Methods and apparatus for bilateral renal neuromodulation |
US7321793B2 (en) * | 2003-06-13 | 2008-01-22 | Biocontrol Medical Ltd. | Vagal stimulation for atrial fibrillation therapy |
US8204591B2 (en) * | 2002-05-23 | 2012-06-19 | Bio Control Medical (B.C.M.) Ltd. | Techniques for prevention of atrial fibrillation |
WO2004110550A2 (en) * | 2003-06-13 | 2004-12-23 | Biocontrol Medical Ltd. | Vagal stimulation for anti-embolic therapy |
US7844346B2 (en) * | 2002-05-23 | 2010-11-30 | Biocontrol Medical Ltd. | Electrode assembly for nerve control |
US7561922B2 (en) * | 2004-12-22 | 2009-07-14 | Biocontrol Medical Ltd. | Construction of electrode assembly for nerve control |
EP1551498A1 (en) * | 2002-07-26 | 2005-07-13 | Transneuronix, Inc. | Improved process for electrostimulation treatment of morbid obesity |
US7277748B2 (en) * | 2002-09-13 | 2007-10-02 | Neuropace, Inc. | Spatiotemporal pattern recognition for neurological event detection and prediction in an implantable device |
US7627384B2 (en) * | 2004-11-15 | 2009-12-01 | Bio Control Medical (B.C.M.) Ltd. | Techniques for nerve stimulation |
US8880192B2 (en) | 2012-04-02 | 2014-11-04 | Bio Control Medical (B.C.M.) Ltd. | Electrode cuffs |
US7844338B2 (en) | 2003-02-03 | 2010-11-30 | Enteromedics Inc. | High frequency obesity treatment |
US7613515B2 (en) * | 2003-02-03 | 2009-11-03 | Enteromedics Inc. | High frequency vagal blockage therapy |
US20040172084A1 (en) * | 2003-02-03 | 2004-09-02 | Knudson Mark B. | Method and apparatus for treatment of gastro-esophageal reflux disease (GERD) |
CA2515368A1 (en) * | 2003-02-13 | 2004-08-26 | Luciano Rossetti | Regulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamus |
JP4469368B2 (en) * | 2003-02-25 | 2010-05-26 | レプトス バイオメディカル インコーポレイテッド | Visceral nerve stimulation for the treatment of obesity |
EP1606011B1 (en) * | 2003-03-10 | 2015-08-19 | Impulse Dynamics N.V. | Apparatus for delivering electrical signals to modify gene expression in cardiac tissue |
US11439815B2 (en) | 2003-03-10 | 2022-09-13 | Impulse Dynamics Nv | Protein activity modification |
US8060197B2 (en) | 2003-05-23 | 2011-11-15 | Bio Control Medical (B.C.M.) Ltd. | Parasympathetic stimulation for termination of non-sinus atrial tachycardia |
US7149574B2 (en) | 2003-06-09 | 2006-12-12 | Palo Alto Investors | Treatment of conditions through electrical modulation of the autonomic nervous system |
US7738952B2 (en) * | 2003-06-09 | 2010-06-15 | Palo Alto Investors | Treatment of conditions through modulation of the autonomic nervous system |
EP1648558A4 (en) * | 2003-06-13 | 2015-05-27 | Biocontrol Medical B C M Ltd | Applications of vagal stimulation |
US8792985B2 (en) | 2003-07-21 | 2014-07-29 | Metacure Limited | Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar |
US20050070970A1 (en) * | 2003-09-29 | 2005-03-31 | Knudson Mark B. | Movement disorder stimulation with neural block |
US20050143378A1 (en) | 2003-12-29 | 2005-06-30 | Yun Anthony J. | Treatment of conditions through pharmacological modulation of the autonomic nervous system |
US7054690B2 (en) * | 2003-10-22 | 2006-05-30 | Intrapace, Inc. | Gastrointestinal stimulation device |
US9002452B2 (en) * | 2003-11-07 | 2015-04-07 | Cardiac Pacemakers, Inc. | Electrical therapy for diastolic dysfunction |
US7676269B2 (en) * | 2003-12-29 | 2010-03-09 | Palo Alto Investors | Treatment of female fertility conditions through modulation of the autonomic nervous system |
US8751003B2 (en) | 2004-02-11 | 2014-06-10 | Ethicon, Inc. | Conductive mesh for neurostimulation |
US8165695B2 (en) * | 2004-02-11 | 2012-04-24 | Ethicon, Inc. | System and method for selectively stimulating different body parts |
US7979137B2 (en) | 2004-02-11 | 2011-07-12 | Ethicon, Inc. | System and method for nerve stimulation |
US20050181341A1 (en) * | 2004-02-12 | 2005-08-18 | Ewing Donald P. | Self-contained electronic musculoskeletal stimulation apparatus and method of use |
US11779768B2 (en) | 2004-03-10 | 2023-10-10 | Impulse Dynamics Nv | Protein activity modification |
WO2006119467A2 (en) | 2005-05-04 | 2006-11-09 | Impulse Dynamics Nv | Protein activity modification |
US8352031B2 (en) * | 2004-03-10 | 2013-01-08 | Impulse Dynamics Nv | Protein activity modification |
JP2007530586A (en) * | 2004-03-25 | 2007-11-01 | ザ ファインスタイン インスティテュート フォー メディカル リサーチ | Nervous hemostasis |
US20160250097A9 (en) * | 2004-03-25 | 2016-09-01 | The Feinstein Institute For Medical Research | Treatment of inflammation by non-invasive stimulation |
US10912712B2 (en) | 2004-03-25 | 2021-02-09 | The Feinstein Institutes For Medical Research | Treatment of bleeding by non-invasive stimulation |
US20050222637A1 (en) * | 2004-03-30 | 2005-10-06 | Transneuronix, Inc. | Tachygastrial electrical stimulation |
WO2006007048A2 (en) | 2004-05-04 | 2006-01-19 | The Cleveland Clinic Foundation | Methods of treating medical conditions by neuromodulation of the sympathetic nervous system |
US20100260669A1 (en) * | 2004-05-13 | 2010-10-14 | Anthony Joonkyoo Yun | Treatment of Seasonal Conditions Through Modulation of the Autonomic Nervous System |
US7899527B2 (en) * | 2004-05-13 | 2011-03-01 | Palo Alto Investors | Treatment of conditions through modulation of the autonomic nervous system during at least one predetermined menstrual cycle phase |
CA2998199A1 (en) * | 2004-06-01 | 2005-12-15 | Kwalata Trading Limited | Methods for use with stem cells involving culturing on a surface with antibodies |
US7803195B2 (en) | 2004-06-03 | 2010-09-28 | Mayo Foundation For Medical Education And Research | Obesity treatment and device |
US7664551B2 (en) * | 2004-07-07 | 2010-02-16 | Medtronic Transneuronix, Inc. | Treatment of the autonomic nervous system |
US20060020277A1 (en) * | 2004-07-20 | 2006-01-26 | Gostout Christopher J | Gastric reshaping devices and methods |
US20060020298A1 (en) * | 2004-07-20 | 2006-01-26 | Camilleri Michael L | Systems and methods for curbing appetite |
US8569277B2 (en) | 2004-08-11 | 2013-10-29 | Palo Alto Investors | Methods of treating a subject for a condition |
ATE532459T1 (en) * | 2004-08-18 | 2011-11-15 | Metacure Ltd | MONITORING, ANALYZING AND REGULATION OF EATING HABITS |
US7623924B2 (en) | 2004-08-31 | 2009-11-24 | Leptos Biomedical, Inc. | Devices and methods for gynecologic hormone modulation in mammals |
US20120277839A1 (en) | 2004-09-08 | 2012-11-01 | Kramer Jeffery M | Selective stimulation to modulate the sympathetic nervous system |
US9205261B2 (en) | 2004-09-08 | 2015-12-08 | The Board Of Trustees Of The Leland Stanford Junior University | Neurostimulation methods and systems |
US7580753B2 (en) | 2004-09-08 | 2009-08-25 | Spinal Modulation, Inc. | Method and system for stimulating a dorsal root ganglion |
EP1799119A4 (en) * | 2004-09-30 | 2010-11-17 | Duocure Inc | Device and method for treating weight disorders |
US7833279B2 (en) * | 2004-11-12 | 2010-11-16 | Enteromedics Inc. | Pancreatic exocrine secretion diversion apparatus and method |
US7483746B2 (en) * | 2004-12-06 | 2009-01-27 | Boston Scientific Neuromodulation Corp. | Stimulation of the stomach in response to sensed parameters to treat obesity |
US20060161217A1 (en) * | 2004-12-21 | 2006-07-20 | Jaax Kristen N | Methods and systems for treating obesity |
AU2005323463B2 (en) | 2004-12-27 | 2009-11-19 | The Feinstein Institutes For Medical Research | Treating inflammatory disorders by electrical vagus nerve stimulation |
US11207518B2 (en) | 2004-12-27 | 2021-12-28 | The Feinstein Institutes For Medical Research | Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway |
US8609082B2 (en) | 2005-01-25 | 2013-12-17 | Bio Control Medical Ltd. | Administering bone marrow progenitor cells or myoblasts followed by application of an electrical current for cardiac repair, increasing blood supply or enhancing angiogenesis |
WO2006088798A2 (en) * | 2005-02-14 | 2006-08-24 | Albert Einstein College Of Medicine Of Yeshiva University | Modulation of hypothalamic atp-sensitive potassium channels |
US9821158B2 (en) * | 2005-02-17 | 2017-11-21 | Metacure Limited | Non-immediate effects of therapy |
US8244371B2 (en) | 2005-03-18 | 2012-08-14 | Metacure Limited | Pancreas lead |
US7580751B2 (en) * | 2005-04-29 | 2009-08-25 | Medtronic, Inc. | Intra-luminal device for gastrointestinal stimulation |
US8588930B2 (en) | 2005-06-07 | 2013-11-19 | Ethicon, Inc. | Piezoelectric stimulation device |
US7856273B2 (en) * | 2005-07-28 | 2010-12-21 | Cyberonics, Inc. | Autonomic nerve stimulation to treat a gastrointestinal disorder |
US7499752B2 (en) * | 2005-07-29 | 2009-03-03 | Cyberonics, Inc. | Selective nerve stimulation for the treatment of eating disorders |
US7822486B2 (en) * | 2005-08-17 | 2010-10-26 | Enteromedics Inc. | Custom sized neural electrodes |
US20090234417A1 (en) * | 2005-11-10 | 2009-09-17 | Electrocore, Inc. | Methods And Apparatus For The Treatment Of Metabolic Disorders |
US8868172B2 (en) * | 2005-12-28 | 2014-10-21 | Cyberonics, Inc. | Methods and systems for recommending an appropriate action to a patient for managing epilepsy and other neurological disorders |
US8725243B2 (en) * | 2005-12-28 | 2014-05-13 | Cyberonics, Inc. | Methods and systems for recommending an appropriate pharmacological treatment to a patient for managing epilepsy and other neurological disorders |
US20070149952A1 (en) * | 2005-12-28 | 2007-06-28 | Mike Bland | Systems and methods for characterizing a patient's propensity for a neurological event and for communicating with a pharmacological agent dispenser |
US20070287931A1 (en) * | 2006-02-14 | 2007-12-13 | Dilorenzo Daniel J | Methods and systems for administering an appropriate pharmacological treatment to a patient for managing epilepsy and other neurological disorders |
TW200734462A (en) | 2006-03-08 | 2007-09-16 | In Motion Invest Ltd | Regulating stem cells |
US20090157138A1 (en) * | 2006-04-18 | 2009-06-18 | Electrocore, Inc. | Methods And Apparatus For Treating Ileus Condition Using Electrical Signals |
US20100057178A1 (en) * | 2006-04-18 | 2010-03-04 | Electrocore, Inc. | Methods and apparatus for spinal cord stimulation using expandable electrode |
US8185206B2 (en) * | 2006-05-17 | 2012-05-22 | Medtronic, Inc. | Electrical stimulation therapy to promote gastric distention for obesity management |
US9020597B2 (en) | 2008-11-12 | 2015-04-28 | Endostim, Inc. | Device and implantation system for electrical stimulation of biological systems |
US8295926B2 (en) | 2006-06-02 | 2012-10-23 | Advanced Neuromodulation Systems, Inc. | Dynamic nerve stimulation in combination with other eating disorder treatment modalities |
US20080027347A1 (en) | 2006-06-23 | 2008-01-31 | Neuro Vista Corporation, A Delaware Corporation | Minimally Invasive Monitoring Methods |
US20080004671A1 (en) * | 2006-06-28 | 2008-01-03 | Alza Corporation | Vagus nerve stimulation via orally delivered apparatus |
JP5191489B2 (en) | 2006-08-23 | 2013-05-08 | エスヴイアイピー 2 エルエルシー | Device and method for changing feeding behavior |
US9345879B2 (en) | 2006-10-09 | 2016-05-24 | Endostim, Inc. | Device and implantation system for electrical stimulation of biological systems |
US9724510B2 (en) | 2006-10-09 | 2017-08-08 | Endostim, Inc. | System and methods for electrical stimulation of biological systems |
US11577077B2 (en) | 2006-10-09 | 2023-02-14 | Endostim, Inc. | Systems and methods for electrical stimulation of biological systems |
US20150224310A1 (en) | 2006-10-09 | 2015-08-13 | Endostim, Inc. | Device and Implantation System for Electrical Stimulation of Biological Systems |
US8498707B2 (en) * | 2008-08-22 | 2013-07-30 | Pacesetter, Inc. | Detection of feeding intent for use in treatment of eating disorders |
US8521291B1 (en) | 2006-10-31 | 2013-08-27 | Pacesetter, Inc. | Dual therapy electrical stimulation system for treating metabolic and eating disorders |
EP2081638A4 (en) * | 2006-11-03 | 2013-06-12 | Gep Technology Inc | Apparatus and methods for minimally invasive obesity treatment |
US8295934B2 (en) * | 2006-11-14 | 2012-10-23 | Neurovista Corporation | Systems and methods of reducing artifact in neurological stimulation systems |
CN101588839A (en) * | 2006-12-06 | 2009-11-25 | 脊髓调制公司 | The grouped leads that is used for spinal stimulation |
US9314618B2 (en) | 2006-12-06 | 2016-04-19 | Spinal Modulation, Inc. | Implantable flexible circuit leads and methods of use |
WO2008070808A2 (en) | 2006-12-06 | 2008-06-12 | Spinal Modulation, Inc. | Expandable stimulation leads and methods of use |
AU2007329252A1 (en) | 2006-12-06 | 2008-06-12 | Spinal Modulation, Inc. | Hard tissue anchors and delivery devices |
US8983624B2 (en) | 2006-12-06 | 2015-03-17 | Spinal Modulation, Inc. | Delivery devices, systems and methods for stimulating nerve tissue on multiple spinal levels |
EP2126785A2 (en) | 2007-01-25 | 2009-12-02 | NeuroVista Corporation | Systems and methods for identifying a contra-ictal condition in a subject |
US20080183097A1 (en) * | 2007-01-25 | 2008-07-31 | Leyde Kent W | Methods and Systems for Measuring a Subject's Susceptibility to a Seizure |
CN101678203A (en) | 2007-01-29 | 2010-03-24 | 脊髓调制公司 | Sutureless lead retention features |
US20080208074A1 (en) * | 2007-02-21 | 2008-08-28 | David Snyder | Methods and Systems for Characterizing and Generating a Patient-Specific Seizure Advisory System |
US8036736B2 (en) | 2007-03-21 | 2011-10-11 | Neuro Vista Corporation | Implantable systems and methods for identifying a contra-ictal condition in a subject |
WO2008121703A1 (en) * | 2007-03-28 | 2008-10-09 | University Of Florida Research Foundation, Inc. | Variational parameter neurostimulation paradigm for treatment of neurologic disease |
US20080281145A1 (en) * | 2007-05-09 | 2008-11-13 | Issam Nemeh | Golgi Stimulator |
US7881784B2 (en) * | 2007-06-14 | 2011-02-01 | The Board Of Regents Of The University Of Texas System | Hepatic electrical stimulation |
US9788744B2 (en) | 2007-07-27 | 2017-10-17 | Cyberonics, Inc. | Systems for monitoring brain activity and patient advisory device |
US20090118777A1 (en) * | 2007-08-09 | 2009-05-07 | Kobi Iki | Efferent and afferent splanchnic nerve stimulation |
US7930033B2 (en) * | 2007-08-17 | 2011-04-19 | Jianfeng Chen | Appendicular and rectal stimulator device for digestive and eating disorders |
WO2009029614A1 (en) | 2007-08-27 | 2009-03-05 | The Feinstein Institute For Medical Research | Devices and methods for inhibiting granulocyte activation by neural stimulation |
TW200918666A (en) * | 2007-09-11 | 2009-05-01 | Wyeth Corp | Attenuated mycoplasma gallisepticum strains |
WO2009035515A1 (en) * | 2007-09-13 | 2009-03-19 | Cardiac Pacemakers, Inc. | Systems for avoiding neural stimulation habituation |
US8352026B2 (en) | 2007-10-03 | 2013-01-08 | Ethicon, Inc. | Implantable pulse generators and methods for selective nerve stimulation |
US7949397B1 (en) | 2007-10-29 | 2011-05-24 | Pacesetter, Inc. | Implantable medical device capable of depressing appetite to control obesity using stochastic resonance electrical stimulation |
US9089707B2 (en) | 2008-07-02 | 2015-07-28 | The Board Of Regents, The University Of Texas System | Systems, methods and devices for paired plasticity |
US8457757B2 (en) | 2007-11-26 | 2013-06-04 | Micro Transponder, Inc. | Implantable transponder systems and methods |
AU2008329716B2 (en) * | 2007-11-26 | 2012-04-19 | Micro Transponder Inc. | Implantable transponder systems and methods |
US9259591B2 (en) * | 2007-12-28 | 2016-02-16 | Cyberonics, Inc. | Housing for an implantable medical device |
US20090171168A1 (en) * | 2007-12-28 | 2009-07-02 | Leyde Kent W | Systems and Method for Recording Clinical Manifestations of a Seizure |
US8565885B2 (en) * | 2008-01-30 | 2013-10-22 | The Board Of Regents Of The University Of Texas System | Ileal electrical stimulation |
US8909346B2 (en) * | 2008-02-15 | 2014-12-09 | Mary Ellen S. Chalmers | Frequency specific micocurrent for treatment of dental indications |
US9662490B2 (en) | 2008-03-31 | 2017-05-30 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug |
WO2009146030A1 (en) | 2008-03-31 | 2009-12-03 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation of t-cell activity |
US20090275997A1 (en) * | 2008-05-01 | 2009-11-05 | Michael Allen Faltys | Vagus nerve stimulation electrodes and methods of use |
US8473062B2 (en) * | 2008-05-01 | 2013-06-25 | Autonomic Technologies, Inc. | Method and device for the treatment of headache |
WO2010006341A1 (en) | 2008-07-11 | 2010-01-14 | Gep Technology, Inc. | Apparatus and methods for minimally invasive obesity treatment |
CA2732309C (en) | 2008-07-30 | 2018-04-10 | Ecole Polytechnique Federale De Lausanne (Epfl) | Apparatus and method for optimized stimulation of a neurological target |
AU2009295227B2 (en) * | 2008-09-19 | 2015-07-16 | Terry William Burton Moore | A method and device for reducing muscle tension through electrical manipulation |
WO2010062622A2 (en) | 2008-10-27 | 2010-06-03 | Spinal Modulation, Inc. | Selective stimulation systems and signal parameters for medical conditions |
EP2783727B1 (en) | 2008-11-12 | 2016-11-09 | Ecole Polytechnique Fédérale de Lausanne | Microfabricated neurostimulation device |
CN102215909B (en) | 2008-11-18 | 2014-09-10 | 赛博恩特医疗器械公司 | Devices and methods for optimizing electrode placement for anti-inflamatory stimulation |
WO2010075518A1 (en) * | 2008-12-23 | 2010-07-01 | Neurovista Corporation | Brain state analysis based on select seizure onset characteristics and clinical manifestations |
US8412336B2 (en) * | 2008-12-29 | 2013-04-02 | Autonomic Technologies, Inc. | Integrated delivery and visualization tool for a neuromodulation system |
US8849390B2 (en) | 2008-12-29 | 2014-09-30 | Cyberonics, Inc. | Processing for multi-channel signals |
US8652129B2 (en) | 2008-12-31 | 2014-02-18 | Medtronic Ardian Luxembourg S.A.R.L. | Apparatus, systems, and methods for achieving intravascular, thermally-induced renal neuromodulation |
US8588933B2 (en) | 2009-01-09 | 2013-11-19 | Cyberonics, Inc. | Medical lead termination sleeve for implantable medical devices |
DK2396072T3 (en) * | 2009-01-14 | 2013-04-08 | Spinal Modulation Inc | STIMULATING ELECTRODE DELIVERY SYSTEM |
US8494641B2 (en) * | 2009-04-22 | 2013-07-23 | Autonomic Technologies, Inc. | Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism |
US9320908B2 (en) * | 2009-01-15 | 2016-04-26 | Autonomic Technologies, Inc. | Approval per use implanted neurostimulator |
US20100185249A1 (en) * | 2009-01-22 | 2010-07-22 | Wingeier Brett M | Method and Devices for Adrenal Stimulation |
US20100268297A1 (en) * | 2009-02-24 | 2010-10-21 | Hans Neisz | Duodenal Stimulation To Induce Satiety |
WO2010101877A1 (en) * | 2009-03-03 | 2010-09-10 | Medtronic, Inc. | Electrical stimulation therapy to promote gastric distention for obesity management |
CA2758459A1 (en) | 2009-03-24 | 2010-10-30 | Spinal Modulation, Inc. | Pain management with stimulation subthreshold to paresthesia |
NL1036784C2 (en) * | 2009-03-30 | 2010-10-04 | Univ Twente | A three-dimensional bifurcating micro-channel construct for regenerative bidirectional neuro-electric interfacing. |
US8321030B2 (en) | 2009-04-20 | 2012-11-27 | Advanced Neuromodulation Systems, Inc. | Esophageal activity modulated obesity therapy |
US8996116B2 (en) | 2009-10-30 | 2015-03-31 | Setpoint Medical Corporation | Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction |
US8612002B2 (en) * | 2009-12-23 | 2013-12-17 | Setpoint Medical Corporation | Neural stimulation devices and systems for treatment of chronic inflammation |
US9211410B2 (en) | 2009-05-01 | 2015-12-15 | Setpoint Medical Corporation | Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
US8340772B2 (en) | 2009-05-08 | 2012-12-25 | Advanced Neuromodulation Systems, Inc. | Brown adipose tissue utilization through neuromodulation |
JP5711221B2 (en) | 2009-05-15 | 2015-04-30 | スパイナル・モデュレーション・インコーポレイテッドSpinal Modulation Inc. | Methods, systems, and devices for neuromodulating spinal cord tissue |
US8786624B2 (en) | 2009-06-02 | 2014-07-22 | Cyberonics, Inc. | Processing for multi-channel signals |
AU2010258792B2 (en) | 2009-06-09 | 2015-07-02 | Setpoint Medical Corporation | Nerve cuff with pocket for leadless stimulator |
MX2012001181A (en) * | 2009-09-21 | 2012-04-30 | Medtronic Inc | Waveforms for electrical stimulation therapy. |
WO2014169145A1 (en) | 2013-04-10 | 2014-10-16 | Setpoint Medical Corporation | Closed-loop vagus nerve stimulation |
US9833621B2 (en) | 2011-09-23 | 2017-12-05 | Setpoint Medical Corporation | Modulation of sirtuins by vagus nerve stimulation |
WO2011067297A1 (en) | 2009-12-01 | 2011-06-09 | ECOLE POLYTECHNIQUE FéDéRALE DE LAUSANNE | Microfabricated neurostimulation device and methods of making and using the same |
US8321012B2 (en) | 2009-12-22 | 2012-11-27 | The Invention Science Fund I, Llc | Device, method, and system for neural modulation as vaccine adjuvant in a vertebrate subject |
US8476227B2 (en) | 2010-01-22 | 2013-07-02 | Ethicon Endo-Surgery, Inc. | Methods of activating a melanocortin-4 receptor pathway in obese subjects |
WO2011092710A2 (en) | 2010-02-01 | 2011-08-04 | Metacure Limited | Gastrointestinal electrical therapy |
US9643019B2 (en) | 2010-02-12 | 2017-05-09 | Cyberonics, Inc. | Neurological monitoring and alerts |
WO2011109080A2 (en) * | 2010-03-01 | 2011-09-09 | Partsch Michael J | A device for intranasal and extranasal neuromodulation |
US20110218820A1 (en) * | 2010-03-02 | 2011-09-08 | Himes David M | Displaying and Manipulating Brain Function Data Including Filtering of Annotations |
US20110219325A1 (en) * | 2010-03-02 | 2011-09-08 | Himes David M | Displaying and Manipulating Brain Function Data Including Enhanced Data Scrolling Functionality |
US11717681B2 (en) | 2010-03-05 | 2023-08-08 | Endostim, Inc. | Systems and methods for treating gastroesophageal reflux disease |
US8447403B2 (en) | 2010-03-05 | 2013-05-21 | Endostim, Inc. | Device and implantation system for electrical stimulation of biological systems |
WO2011121089A1 (en) | 2010-04-01 | 2011-10-06 | Ecole Polytechnique Federale De Lausanne (Epfl) | Device for interacting with neurological tissue and methods of making and using the same |
EP2568904B1 (en) | 2010-05-10 | 2019-10-02 | Spinal Modulation Inc. | Device for reducing migration |
US8805519B2 (en) | 2010-09-30 | 2014-08-12 | Nevro Corporation | Systems and methods for detecting intrathecal penetration |
EP3449856B1 (en) | 2010-10-25 | 2023-06-28 | Medtronic Ardian Luxembourg S.à.r.l. | Device for evaluation and feedback of neuromodulation treatment |
AU2012212150B2 (en) | 2011-02-02 | 2016-09-29 | Spinal Modulation, Inc | Devices, systems and methods for the targeted treatment of movement disorders |
EP2696792B8 (en) | 2011-04-14 | 2018-05-23 | Endostim, Inc. | Systems for treating gastroesophageal reflux disease |
CN103619405B (en) | 2011-05-09 | 2015-11-25 | 赛博恩特医疗器械公司 | The individual pulse being used for the treatment of the cholinergic anti-inflammatory pathway of chronic inflammatory disease activates |
US8923974B2 (en) * | 2011-05-13 | 2014-12-30 | Boston Scientific Neuromodulation Corporation | System and method for electrical modulation of the posterior Longitudinal ligament |
US8688233B2 (en) * | 2011-06-23 | 2014-04-01 | Boston Scientific Neuromodulation Corporation | System and method for spinal cord stimulation to treat motor disorders |
US20130172774A1 (en) | 2011-07-01 | 2013-07-04 | Neuropace, Inc. | Systems and Methods for Assessing the Effectiveness of a Therapy Including a Drug Regimen Using an Implantable Medical Device |
WO2013033673A1 (en) | 2011-09-02 | 2013-03-07 | Endostim, Inc. | Endoscopic lead implantation method |
US9925367B2 (en) | 2011-09-02 | 2018-03-27 | Endostim, Inc. | Laparoscopic lead implantation method |
EP2788078B1 (en) | 2011-12-09 | 2020-09-02 | Metavention, Inc. | Therapeutic neuromodulation of the hepatic system |
AU2013229776B2 (en) | 2012-03-08 | 2016-12-15 | Medtronic Af Luxembourg S.A.R.L. | Biomarker sampling in the context of neuromodulation devices and associated systems |
WO2013134548A2 (en) | 2012-03-08 | 2013-09-12 | Medtronic Ardian Luxembourg S.A.R.L. | Ovarian neuromodulation and associated systems and methods |
US9572983B2 (en) | 2012-03-26 | 2017-02-21 | Setpoint Medical Corporation | Devices and methods for modulation of bone erosion |
US9456916B2 (en) | 2013-03-12 | 2016-10-04 | Medibotics Llc | Device for selectively reducing absorption of unhealthy food |
US9833614B1 (en) | 2012-06-22 | 2017-12-05 | Nevro Corp. | Autonomic nervous system control via high frequency spinal cord modulation, and associated systems and methods |
WO2014032030A2 (en) | 2012-08-23 | 2014-02-27 | Endostim, Inc. | Device and implantation system for electrical stimulation of biological systems |
US20140110296A1 (en) | 2012-10-19 | 2014-04-24 | Medtronic Ardian Luxembourg S.A.R.L. | Packaging for Catheter Treatment Devices and Associated Devices, Systems, and Methods |
EP3912674A1 (en) | 2013-01-21 | 2021-11-24 | Cala Health, Inc. | Devices for controlling tremor |
US8880167B2 (en) * | 2013-02-13 | 2014-11-04 | Flint Hills Scientific, Llc | Selective recruitment and activation of fiber types in nerves for the control of undesirable brain state changes |
US9498619B2 (en) | 2013-02-26 | 2016-11-22 | Endostim, Inc. | Implantable electrical stimulation leads |
US9067070B2 (en) | 2013-03-12 | 2015-06-30 | Medibotics Llc | Dysgeusia-inducing neurostimulation for modifying consumption of a selected nutrient type |
US9011365B2 (en) | 2013-03-12 | 2015-04-21 | Medibotics Llc | Adjustable gastrointestinal bifurcation (AGB) for reduced absorption of unhealthy food |
US10238673B2 (en) | 2013-03-13 | 2019-03-26 | Genetic Disease Investigators, LLC | Methods and compositions for treatment of dry eye and correction of organ dysfunctions |
US9271953B2 (en) | 2013-03-13 | 2016-03-01 | Genetic Disease Investigators, LLC | Methods for correction of organ dysfunction |
KR102363552B1 (en) | 2013-05-30 | 2022-02-15 | 그라함 에이치. 크리시 | Topical neurological stimulation |
US11229789B2 (en) | 2013-05-30 | 2022-01-25 | Neurostim Oab, Inc. | Neuro activator with controller |
US20140369969A1 (en) * | 2013-06-13 | 2014-12-18 | Palo Alto Investors | Methods for treating conditions by restoring central nervous system endocrine gland function, and compositions and devices for practicing the same |
CN105848708A (en) | 2013-09-03 | 2016-08-10 | 恩多斯蒂姆股份有限公司 | Methods and systems of electrode polarity switching in electrical stimulation therapy |
US10123896B2 (en) | 2014-03-06 | 2018-11-13 | Mayo Foundation For Medical Education And Research | Apparatus and methods of inducing weight loss using blood flow control |
US10194980B1 (en) | 2014-03-28 | 2019-02-05 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for catheter-based renal neuromodulation |
US10194979B1 (en) | 2014-03-28 | 2019-02-05 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for catheter-based renal neuromodulation |
US9980766B1 (en) | 2014-03-28 | 2018-05-29 | Medtronic Ardian Luxembourg S.A.R.L. | Methods and systems for renal neuromodulation |
EP3476430B1 (en) | 2014-05-16 | 2020-07-01 | Aleva Neurotherapeutics SA | Device for interacting with neurological tissue |
US11311718B2 (en) | 2014-05-16 | 2022-04-26 | Aleva Neurotherapeutics Sa | Device for interacting with neurological tissue and methods of making and using the same |
BR112016025203B1 (en) | 2014-06-02 | 2022-09-06 | Cala Health, Inc | TRANSCUTANEOUS SYSTEM TO TREAT A PATIENT SUFFERING FROM TREMOR |
US9403011B2 (en) | 2014-08-27 | 2016-08-02 | Aleva Neurotherapeutics | Leadless neurostimulator |
US9474894B2 (en) | 2014-08-27 | 2016-10-25 | Aleva Neurotherapeutics | Deep brain stimulation lead |
US11311725B2 (en) | 2014-10-24 | 2022-04-26 | Setpoint Medical Corporation | Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation |
US9597507B2 (en) | 2014-10-31 | 2017-03-21 | Medtronic, Inc. | Paired stimulation pulses based on sensed compound action potential |
US9682234B2 (en) | 2014-11-17 | 2017-06-20 | Endostim, Inc. | Implantable electro-medical device programmable for improved operational life |
US11406833B2 (en) | 2015-02-03 | 2022-08-09 | Setpoint Medical Corporation | Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator |
US10376308B2 (en) | 2015-02-05 | 2019-08-13 | Axon Therapies, Inc. | Devices and methods for treatment of heart failure by splanchnic nerve ablation |
US10130813B2 (en) | 2015-02-10 | 2018-11-20 | Neuropace, Inc. | Seizure onset classification and stimulation parameter selection |
US11077301B2 (en) | 2015-02-21 | 2021-08-03 | NeurostimOAB, Inc. | Topical nerve stimulator and sensor for bladder control |
US10376145B2 (en) | 2015-02-24 | 2019-08-13 | Elira, Inc. | Systems and methods for enabling a patient to achieve a weight loss objective using an electrical dermal patch |
US10154922B1 (en) | 2015-02-24 | 2018-12-18 | Elira, Inc. | Systems and methods for enabling appetite modulation and/or improving dietary compliance using percutaneous electrical neurostimulation |
US10864367B2 (en) | 2015-02-24 | 2020-12-15 | Elira, Inc. | Methods for using an electrical dermal patch in a manner that reduces adverse patient reactions |
WO2016138176A1 (en) | 2015-02-24 | 2016-09-01 | Elira Therapeutics Llc | Systems and methods for enabling appetite modulation and/or improving dietary compliance using an electro-dermal patch |
US10765863B2 (en) | 2015-02-24 | 2020-09-08 | Elira, Inc. | Systems and methods for using a transcutaneous electrical stimulation device to deliver titrated therapy |
US10335302B2 (en) | 2015-02-24 | 2019-07-02 | Elira, Inc. | Systems and methods for using transcutaneous electrical stimulation to enable dietary interventions |
US9956393B2 (en) | 2015-02-24 | 2018-05-01 | Elira, Inc. | Systems for increasing a delay in the gastric emptying time for a patient using a transcutaneous electro-dermal patch |
US20220062621A1 (en) | 2015-02-24 | 2022-03-03 | Elira, Inc. | Electrical Stimulation-Based Weight Management System |
US11103696B2 (en) | 2015-05-05 | 2021-08-31 | Cosmo Haralambidis | Device for electrical stimulation of peridontal complex and surrounding tissue |
JP6860503B2 (en) | 2015-05-05 | 2021-04-14 | コスモ ハラランビディス, | Device for electrical stimulation of periodontal complex and surrounding tissue |
US10765856B2 (en) | 2015-06-10 | 2020-09-08 | Cala Health, Inc. | Systems and methods for peripheral nerve stimulation to treat tremor with detachable therapy and monitoring units |
US10603482B2 (en) | 2015-09-23 | 2020-03-31 | Cala Health, Inc. | Systems and methods for peripheral nerve stimulation in the finger or hand to treat hand tremors |
US10207110B1 (en) | 2015-10-13 | 2019-02-19 | Axon Therapies, Inc. | Devices and methods for treatment of heart failure via electrical modulation of a splanchnic nerve |
US10596367B2 (en) | 2016-01-13 | 2020-03-24 | Setpoint Medical Corporation | Systems and methods for establishing a nerve block |
US11471681B2 (en) | 2016-01-20 | 2022-10-18 | Setpoint Medical Corporation | Batteryless implantable microstimulators |
US10695569B2 (en) | 2016-01-20 | 2020-06-30 | Setpoint Medical Corporation | Control of vagal stimulation |
EP3405255A4 (en) | 2016-01-20 | 2019-10-16 | Setpoint Medical Corporation | Implantable microstimulators and inductive charging systems |
JP6952699B2 (en) | 2016-01-21 | 2021-10-20 | カラ ヘルス, インコーポレイテッドCala Health, Inc. | Systems, methods and devices for peripheral nerve regulation to treat diseases associated with overactive bladder |
US10583304B2 (en) | 2016-01-25 | 2020-03-10 | Setpoint Medical Corporation | Implantable neurostimulator having power control and thermal regulation and methods of use |
EP3411111A1 (en) | 2016-02-02 | 2018-12-12 | Aleva Neurotherapeutics SA | Treatment of autoimmune diseases with deep brain stimulation |
US10524859B2 (en) | 2016-06-07 | 2020-01-07 | Metavention, Inc. | Therapeutic tissue modulation devices and methods |
CN109689151A (en) | 2016-07-08 | 2019-04-26 | 卡拉健康公司 | With lucky N number of electrode and the system and method for improving the dry N number of nerve of electrode stimulating |
WO2018019856A1 (en) * | 2016-07-25 | 2018-02-01 | Galvani Bioelectronics Limited | Neuromodulation of adrenal gland |
US11154354B2 (en) | 2016-07-29 | 2021-10-26 | Axon Therapies, Inc. | Devices, systems, and methods for treatment of heart failure by splanchnic nerve ablation |
WO2018094207A1 (en) | 2016-11-17 | 2018-05-24 | Endostim, Inc. | Modular stimulation system for the treatment of gastrointestinal disorders |
US10980999B2 (en) | 2017-03-09 | 2021-04-20 | Nevro Corp. | Paddle leads and delivery tools, and associated systems and methods |
US11331480B2 (en) | 2017-04-03 | 2022-05-17 | Cala Health, Inc. | Systems, methods and devices for peripheral neuromodulation for treating diseases related to overactive bladder |
US11173307B2 (en) | 2017-08-14 | 2021-11-16 | Setpoint Medical Corporation | Vagus nerve stimulation pre-screening test |
US10729907B2 (en) | 2017-10-20 | 2020-08-04 | Neuropace, Inc. | Systems and methods for clinical decision making for a patient receiving a neuromodulation therapy based on deep learning |
CN111601636A (en) | 2017-11-07 | 2020-08-28 | Oab神经电疗科技公司 | Non-invasive neural activator with adaptive circuit |
WO2019118976A1 (en) | 2017-12-17 | 2019-06-20 | Axon Therapies, Inc. | Methods and devices for endovascular ablation of a splanchnic nerve |
EP3740274A4 (en) | 2018-01-17 | 2021-10-27 | Cala Health, Inc. | Systems and methods for treating inflammatory bowel disease through peripheral nerve stimulation |
US11751939B2 (en) | 2018-01-26 | 2023-09-12 | Axon Therapies, Inc. | Methods and devices for endovascular ablation of a splanchnic nerve |
US10702692B2 (en) | 2018-03-02 | 2020-07-07 | Aleva Neurotherapeutics | Neurostimulation device |
EP3758793A4 (en) | 2018-03-29 | 2021-12-08 | Nevro Corp. | Leads having sidewall openings, and associated systems and methods |
CN112218678A (en) * | 2018-03-29 | 2021-01-12 | 内弗洛公司 | Therapeutic modulation to treat glycemic abnormalities (including type 2 diabetes) and/or reduce the level of HBA1C and related systems and methods |
US11260229B2 (en) | 2018-09-25 | 2022-03-01 | The Feinstein Institutes For Medical Research | Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation |
US11481578B2 (en) | 2019-02-22 | 2022-10-25 | Neuropace, Inc. | Systems and methods for labeling large datasets of physiological records based on unsupervised machine learning |
US11612750B2 (en) | 2019-03-19 | 2023-03-28 | Neuropace, Inc. | Methods and systems for optimizing therapy using stimulation mimicking natural seizures |
WO2020257763A1 (en) | 2019-06-20 | 2020-12-24 | Axon Therapies, Inc. | Methods and devices for endovascular ablation of a splanchnic nerve |
CN114126704A (en) | 2019-06-26 | 2022-03-01 | 神经科学技术有限责任公司 | Non-invasive neural activator with adaptive circuit |
US11890468B1 (en) | 2019-10-03 | 2024-02-06 | Cala Health, Inc. | Neurostimulation systems with event pattern detection and classification |
WO2021126921A1 (en) | 2019-12-16 | 2021-06-24 | Neurostim Solutions, Llc | Non-invasive nerve activator with boosted charge delivery |
ES2960299T3 (en) | 2020-01-17 | 2024-03-04 | Axon Therapies Inc | Devices for endovascular ablation of a splanchnic nerve |
US11938324B2 (en) | 2020-05-21 | 2024-03-26 | The Feinstein Institutes For Medical Research | Systems and methods for vagus nerve stimulation |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5188104A (en) * | 1991-02-01 | 1993-02-23 | Cyberonics, Inc. | Treatment of eating disorders by nerve stimulation |
US5263480A (en) * | 1991-02-01 | 1993-11-23 | Cyberonics, Inc. | Treatment of eating disorders by nerve stimulation |
US5540734A (en) * | 1994-09-28 | 1996-07-30 | Zabara; Jacob | Cranial nerve stimulation treatments using neurocybernetic prosthesis |
US5700282A (en) * | 1995-10-13 | 1997-12-23 | Zabara; Jacob | Heart rhythm stabilization using a neurocybernetic prosthesis |
US6129685A (en) * | 1994-02-09 | 2000-10-10 | The University Of Iowa Research Foundation | Stereotactic hypothalamic obesity probe |
US6169924B1 (en) * | 1999-04-27 | 2001-01-02 | T. Stuart Meloy | Spinal cord stimulation |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR200511A1 (en) * | 1974-01-25 | 1974-11-15 | Trabucco H | CATHETER ELECTRODE FOR EPICARDIC AND INTRAMIOCARDIC ELECTRIC CARDIAC STIMULATION |
US4256115A (en) * | 1976-12-20 | 1981-03-17 | American Technology, Inc. | Leadless cardiac pacer |
US5095905A (en) * | 1990-06-07 | 1992-03-17 | Medtronic, Inc. | Implantable neural electrode |
IT1260485B (en) * | 1992-05-29 | 1996-04-09 | PROCEDURE AND DEVICE FOR THE TREATMENT OF THE OBESITY OF A PATIENT | |
US5782874A (en) * | 1993-05-28 | 1998-07-21 | Loos; Hendricus G. | Method and apparatus for manipulating nervous systems |
US5458626A (en) * | 1993-12-27 | 1995-10-17 | Krause; Horst E. | Method of electrical nerve stimulation for acceleration of tissue healing |
DE4433111A1 (en) * | 1994-09-16 | 1996-03-21 | Fraunhofer Ges Forschung | Cuff electrode |
US6006134A (en) * | 1998-04-30 | 1999-12-21 | Medtronic, Inc. | Method and device for electronically controlling the beating of a heart using venous electrical stimulation of nerve fibers |
US5782798A (en) * | 1996-06-26 | 1998-07-21 | Medtronic, Inc. | Techniques for treating eating disorders by brain stimulation and drug infusion |
US6246912B1 (en) * | 1996-06-27 | 2001-06-12 | Sherwood Services Ag | Modulated high frequency tissue modification |
WO1998009679A1 (en) * | 1996-09-05 | 1998-03-12 | The Governors Of The University Of Alberta | Gastro-intestinal electrical pacemaker |
US5861014A (en) * | 1997-04-30 | 1999-01-19 | Medtronic, Inc. | Method and apparatus for sensing a stimulating gastrointestinal tract on-demand |
WO1999038563A1 (en) * | 1998-02-02 | 1999-08-05 | The Trustees Of Columbia University In The City Of New York | Electrical system for weight loss and laparoscopic implantation thereof |
US6141588A (en) * | 1998-07-24 | 2000-10-31 | Intermedics Inc. | Cardiac simulation system having multiple stimulators for anti-arrhythmia therapy |
US7599736B2 (en) | 2001-07-23 | 2009-10-06 | Dilorenzo Biomedical, Llc | Method and apparatus for neuromodulation and physiologic modulation for the treatment of metabolic and neuropsychiatric disease |
US20030027998A1 (en) * | 1998-10-30 | 2003-02-06 | Holtzman Douglas A. | Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses |
US6606523B1 (en) * | 1999-04-14 | 2003-08-12 | Transneuronix Inc. | Gastric stimulator apparatus and method for installing |
US6178349B1 (en) * | 1999-04-15 | 2001-01-23 | Medtronic, Inc. | Drug delivery neural stimulation device for treatment of cardiovascular disorders |
US6587719B1 (en) * | 1999-07-01 | 2003-07-01 | Cyberonics, Inc. | Treatment of obesity by bilateral vagus nerve stimulation |
US6438423B1 (en) * | 2000-01-20 | 2002-08-20 | Electrocore Technique, Llc | Method of treating complex regional pain syndromes by electrical stimulation of the sympathetic nerve chain |
US6356787B1 (en) * | 2000-02-24 | 2002-03-12 | Electro Core Techniques, Llc | Method of treating facial blushing by electrical stimulation of the sympathetic nerve chain |
US6356786B1 (en) * | 2000-01-20 | 2002-03-12 | Electrocore Techniques, Llc | Method of treating palmar hyperhydrosis by electrical stimulation of the sympathetic nervous chain |
US6862479B1 (en) * | 2000-08-30 | 2005-03-01 | Advanced Bionics Corporation | Spinal cord stimulation as a therapy for sexual dysfunction |
WO2002032499A1 (en) * | 2000-09-14 | 2002-04-25 | Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California | Method and apparatus to treat disorders of gastrointestinal peristalsis |
US6487446B1 (en) * | 2000-09-26 | 2002-11-26 | Medtronic, Inc. | Method and system for spinal cord stimulation prior to and during a medical procedure |
US6591137B1 (en) * | 2000-11-09 | 2003-07-08 | Neuropace, Inc. | Implantable neuromuscular stimulator for the treatment of gastrointestinal disorders |
US6928320B2 (en) * | 2001-05-17 | 2005-08-09 | Medtronic, Inc. | Apparatus for blocking activation of tissue or conduction of action potentials while other tissue is being therapeutically activated |
US20060116736A1 (en) * | 2001-07-23 | 2006-06-01 | Dilorenzo Daniel J | Method, apparatus, and surgical technique for autonomic neuromodulation for the treatment of obesity |
US20060167498A1 (en) * | 2001-07-23 | 2006-07-27 | Dilorenzo Daniel J | Method, apparatus, and surgical technique for autonomic neuromodulation for the treatment of disease |
US7236822B2 (en) * | 2002-03-22 | 2007-06-26 | Leptos Biomedical, Inc. | Wireless electric modulation of sympathetic nervous system |
US7239912B2 (en) * | 2002-03-22 | 2007-07-03 | Leptos Biomedical, Inc. | Electric modulation of sympathetic nervous system |
US7483746B2 (en) * | 2004-12-06 | 2009-01-27 | Boston Scientific Neuromodulation Corp. | Stimulation of the stomach in response to sensed parameters to treat obesity |
US20060161217A1 (en) * | 2004-12-21 | 2006-07-20 | Jaax Kristen N | Methods and systems for treating obesity |
-
2002
- 2002-07-19 US US10/198,871 patent/US7599736B2/en not_active Expired - Lifetime
-
2004
- 2004-06-21 US US10/872,549 patent/US7529582B1/en not_active Expired - Fee Related
-
2009
- 2009-05-05 US US12/387,638 patent/US20090216286A1/en not_active Abandoned
- 2009-08-09 US US12/462,903 patent/US20090306739A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5188104A (en) * | 1991-02-01 | 1993-02-23 | Cyberonics, Inc. | Treatment of eating disorders by nerve stimulation |
US5263480A (en) * | 1991-02-01 | 1993-11-23 | Cyberonics, Inc. | Treatment of eating disorders by nerve stimulation |
US6129685A (en) * | 1994-02-09 | 2000-10-10 | The University Of Iowa Research Foundation | Stereotactic hypothalamic obesity probe |
US5540734A (en) * | 1994-09-28 | 1996-07-30 | Zabara; Jacob | Cranial nerve stimulation treatments using neurocybernetic prosthesis |
US5700282A (en) * | 1995-10-13 | 1997-12-23 | Zabara; Jacob | Heart rhythm stabilization using a neurocybernetic prosthesis |
US6169924B1 (en) * | 1999-04-27 | 2001-01-02 | T. Stuart Meloy | Spinal cord stimulation |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9707034B2 (en) | 2002-07-01 | 2017-07-18 | Recor Medical, Inc. | Intraluminal method and apparatus for ablating nerve tissue |
US9700372B2 (en) | 2002-07-01 | 2017-07-11 | Recor Medical, Inc. | Intraluminal methods of ablating nerve tissue |
US8862233B2 (en) | 2003-02-03 | 2014-10-14 | Enteromedics Inc. | Electrode band system and methods of using the system to treat obesity |
US8369952B2 (en) | 2003-02-03 | 2013-02-05 | Enteromedics, Inc. | Bulimia treatment |
US9586046B2 (en) | 2003-02-03 | 2017-03-07 | Enteromedics, Inc. | Electrode band system and methods of using the system to treat obesity |
US7986995B2 (en) | 2003-02-03 | 2011-07-26 | Enteromedics Inc. | Bulimia treatment |
US8103349B2 (en) | 2005-08-17 | 2012-01-24 | Enteromedics Inc. | Neural electrode treatment |
US10499937B2 (en) | 2006-05-19 | 2019-12-10 | Recor Medical, Inc. | Ablation device with optimized input power profile and method of using the same |
US8483830B2 (en) | 2008-04-04 | 2013-07-09 | Enteromedics Inc. | Methods and systems for glucose regulation |
US10722714B2 (en) | 2008-04-04 | 2020-07-28 | Reshape Lifesciences, Inc. | Methods and systems for glucose regulation |
US9333340B2 (en) | 2008-04-04 | 2016-05-10 | Enteromedics Inc. | Methods and systems for glucose regulation |
US9974955B2 (en) | 2008-04-04 | 2018-05-22 | Reshape Lifesciences Inc. | Methods and systems for glucose regulation |
US20090254143A1 (en) * | 2008-04-04 | 2009-10-08 | Tweden Katherine S | Methods and systems for glucose regulation |
US8974445B2 (en) | 2009-01-09 | 2015-03-10 | Recor Medical, Inc. | Methods and apparatus for treatment of cardiac valve insufficiency |
US9662486B2 (en) | 2010-01-22 | 2017-05-30 | Ethicon Endo-Surgery, Inc. | Methods and devices for activating brown adipose tissue using electrical energy |
AU2010343059B2 (en) * | 2010-01-22 | 2015-04-02 | Ethicon Endo-Surgery, Inc. | Methods and devices for activating brown adipose tissue using electrical energy |
US9968778B2 (en) | 2010-06-11 | 2018-05-15 | Reshape Lifesciences Inc. | Neural modulation devices and methods |
US9358395B2 (en) | 2010-06-11 | 2016-06-07 | Enteromedics Inc. | Neural modulation devices and methods |
US8825164B2 (en) | 2010-06-11 | 2014-09-02 | Enteromedics Inc. | Neural modulation devices and methods |
US10080884B2 (en) | 2014-12-29 | 2018-09-25 | Ethicon Llc | Methods and devices for activating brown adipose tissue using electrical energy |
US10092738B2 (en) | 2014-12-29 | 2018-10-09 | Ethicon Llc | Methods and devices for inhibiting nerves when activating brown adipose tissue |
US10207102B2 (en) | 2014-12-29 | 2019-02-19 | Ethicon Llc | Methods and devices for activating brown adipose tissue using electrical energy |
US10391298B2 (en) | 2014-12-29 | 2019-08-27 | Ethicon Llc | Methods and devices for activating brown adipose tissue using electrical energy |
US10960201B2 (en) | 2014-12-29 | 2021-03-30 | Ethicon Llc | Methods and devices for inhibiting nerves when activating brown adipose tissue |
US10994123B2 (en) | 2014-12-29 | 2021-05-04 | Cilag Gmbh International | Methods and devices for activating brown adipose tissue using electrical energy |
US11679252B2 (en) | 2014-12-29 | 2023-06-20 | Cilag Gmbh International | Methods and devices for activating brown adipose tissue using electrical energy |
Also Published As
Publication number | Publication date |
---|---|
US7529582B1 (en) | 2009-05-05 |
US20090216286A1 (en) | 2009-08-27 |
US20030018367A1 (en) | 2003-01-23 |
US7599736B2 (en) | 2009-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7599736B2 (en) | Method and apparatus for neuromodulation and physiologic modulation for the treatment of metabolic and neuropsychiatric disease | |
US20060116736A1 (en) | Method, apparatus, and surgical technique for autonomic neuromodulation for the treatment of obesity | |
US20060167498A1 (en) | Method, apparatus, and surgical technique for autonomic neuromodulation for the treatment of disease | |
EP2254462B1 (en) | Apparatus for programming of autonomic neuromodulation for the treatment of obesity | |
US11529513B2 (en) | Neuromodulation system | |
US20070162085A1 (en) | Method, apparatus, surgical technique, and stimulation parameters for autonomic neuromodulation for the treatment of obesity | |
US7890185B2 (en) | Treatment of disorders by unidirectional nerve stimulation | |
US7734355B2 (en) | Treatment of disorders by unidirectional nerve stimulation | |
US20090118780A1 (en) | Method and apparatus for conformal electrodes for autonomic neuromodulation for the treatment of obesity and other conditions | |
US20070106337A1 (en) | Methods And Apparatus For Treating Disorders Through Neurological And/Or Muscular Intervention | |
US7689276B2 (en) | Dynamic nerve stimulation for treatment of disorders | |
US6609025B2 (en) | Treatment of obesity by bilateral sub-diaphragmatic nerve stimulation | |
US7643880B2 (en) | Methods and systems for selectively inhibiting neural transmission of somatic fibers | |
US7613515B2 (en) | High frequency vagal blockage therapy | |
US20080147137A1 (en) | Inhibition of sympathetic nerves | |
US20100249873A1 (en) | Direct and Indirect Control of Muscle for the Treatment of Pathologies | |
US20030181959A1 (en) | Wireless electric modulation of sympathetic nervous system | |
US20190329042A1 (en) | Method, apparatus, surgical technique, and optimal stimulation parameters for noninvasive & minimally invasive autonomic vector neuromodulation for physiologic optimization and for the treatment of obesity, cardiac disease, pulmonary disorders, hypertension, and other conditions | |
US20230121038A1 (en) | Neuromodulation system | |
US20200268536A1 (en) | Method, apparatus, surgical technique, and optimal stimulation parameters for noninvasive & minimally invasive autonomic vector neuromodulation for the treatment of obesity, cardiac disease, pulmonary disorders, hypertension, and other conditions | |
EP3319685B1 (en) | Apparatus for modulation of effector organs | |
IL160483A (en) | Apparatus for treatment of disorders by unidirectional nerve stimulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |